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Preterm birth is the national leading cause of neonatal morbidity and mortality. 
Nearly 500,000 infants are born prematurely each year in the United States and the 
annual cost of prematurity averages over $26 billion dollars. Despite multiple 
interventions to reduce infection related prematurity many spontaneous preterm births 
remain attributed infection and inflammation. We hypothesize that prevention of 
infection and inflammation related spontaneous preterm birth is possible through 
enrichment, stabilization, and normalization of the vaginal microbiome. To test this 
hypothesis we will perform a randomized, double blind, placebo-controlled trial of 
intravaginal Lactobacillus probiotic in women at high-risk for spontaneous preterm 
birth. Primary outcome will be reduction frequency of spontaneous preterm birth prior 
to 37 weeks completed gestation. Results of this study will heighten understanding of 
the role of the normal vaginal flora in pregnancy and potentially uncover a new 
intervention capable of reducing preterm birth and the complications of prematurity.
 1 
CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND 
 Preterm birth, defined as obstetrical delivery prior to 37 weeks completed 
gestation, is the leading cause of infant mortality in the United States.1,2 Approximately 
34% of infant deaths in the first year of life are attributed to preterm birth, and 
premature delivery affects over 11% of pregnancies nationwide.2,3 The incidence of 
preterm birth in the United States surpasses most developed countries, as one-half 
million infants are born prematurely each year.4 In addition to an increased risk of 
mortality, these infants are at elevated risk for short and long-term health conditions.5,6 
 Premature birth is associated with complex health conditions in the neonatal 
period and first year of life, which include acute respiratory distress syndrome, 
necrotizing enterocolitis, and sepsis.5,7 Additionally, many infants born prematurely 
proceed to suffer from lifelong health complications such as cerebral palsy, mental 
retardation, and asthma.8,9 Due to the short and long-term implications of prematurity, 
a significant economic burden is also associated with preterm birth. In 2005, the cost of 
prematurity in the United States was estimated at 26.2 billion dollars.10 Of that sum, 
16.9 billion dollars was spent on medical care for premature children.10 An additional 
1.1 billion dollars was spent on special education services for neurodevelopmental and 
physical disabilities associated with preterm birth, highlighting the long-term impact of 
prematurity.10 The medical complications and financial cost of preterm delivery are 
inversely related to gestational age at delivery, as the most premature infants typically 
suffer from the most serious conditions and require the most complex treatment.7-9,11  
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Preterm delivery is classified as medically indicated or spontaneous, depending 
on clinical course.12 Indicated preterm birth is medically induced due to risk of maternal 
or fetal morbidity or mortality if gestation continues to full term.12,13 Complications that 
warrant induced preterm delivery include placenta previa and severe preeclampsia or 
eclampsia.13,14 Spontaneous preterm birth, which accounts for 70-75% of preterm births 
in the United States, is characterized by premature activation of the physiologic 
processes underlying full-term labor.15,16 These processes involve cervical ripening, 
cervical dilation and effacement, increased myometrial contractility, and activation of 
the decidua with rupture of the amniotic membranes.16,17 Pathologic mechanisms 
capable of inciting the cascade that results in spontaneous preterm parturition include 
myometrial stretch, physiologic or psychosocial stress, precocious activation of the fetal-
maternal hypothalamic-pituitary axis, and intrauterine infection and inflammation.15-17 
Many lifestyle and physiologic variables increase risk for spontaneous preterm birth, but 
the most predictive factor for spontaneous preterm delivery is history of premature 
birth in previous pregnancy.18-20 Women with a history of spontaneous preterm birth in 
a previous singleton gestation are at a 2.5-5.6 fold increased risk for spontaneous 
preterm birth in their next singleton pregnancy, thus indicating significant predisposition 
to preterm birth in a subset of the population.21,22 
 The recommended interventions to attenuate risk of preterm birth in women 
with a history of spontaneous preterm birth during a singleton gestation are life-style 
modification (e.g. smoking cessation), progesterone supplementation, and cervical 
cerclage.23,24 Weekly intramuscular injections of 17 alpha-hydroxyprogesterone 
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caproate, a progesterone metabolite, decreased risk of spontaneous preterm birth 
among women with a history of singleton spontaneous preterm birth by 33% in a 
randomized, double blind, placebo-controlled trial.25 Cervical cerclage, a therapeutic 
option for pregnant women with sonographic evidence of short cervical length, also 
shows benefit in reducing preterm birth among high risk women. A meta-analysis of 
cervical cerclage in women with prior spontaneous preterm birth and short sonographic 
cervix found a 30-38% reduction in preterm birth and a 37% reduction in neonatal 
morbidity and mortality with cerclage placement.26 Though the mechanism behind the 
success of progesterone and cervical cerclage is incompletely understood, these 
therapies are promising interventions. Unfortunately, the rate of spontaneous preterm 
birth among high-risk women who receive progesterone or cerclage is still 30-40%, 
which is over three times the national average.25-27 Thus, novel interventions are needed 
to address the burden of preterm birth in this population.   
As previously mentioned, intrauterine infection and inflammation are capable of 
inducing premature labor.28 The inflammatory cascade that is a result of microbial 
infection is implicated in 25-50% of spontaneous preterm births despite standard 
gestational screening and treatment of infectious conditions such as chlamydia and 
bacteriuria.29-31 Most cases of intrauterine infection are subclinical and due to the 
ascension of vaginal bacterial pathogens or opportunists.15,22,30 Opportunistic organisms 
of the vaginal flora such as Ureaplasma urealyticum, Gardnerella vaginalis, Mycoplasma 
hominis, Streptococcus agalactiae, and Escherichia coli are the organisms most often 
identified in the amniotic fluid or placenta of women who experience infection related 
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spontaneous preterm birth.15,30 An effective intervention for the prevention of 
subclinical vaginal and intrauterine infection and inflammation must be developed to 
further reduce the burden of spontaneous prematurity among women at high-risk.  
To date, the reduction of subclinical, asymptomatic vaginal infections during 
gestation has focused on antibiotic treatment or prevention of asymptomatic bacterial 
vaginosis (BV). Evidence indicates that asymptomatic BV is a risk factor for preterm birth 
and the anaerobic organisms most commonly cultured from women experiencing 
preterm birth define BV.32,33 Thus, it seems reasonable that treatment or prevention of 
BV during gestation would reduce the rate of infection related prematurity. However, 
trials of antibiotic therapy for treatment or prevention of BV during gestation show 
limited success in decreasing the rate of spontaneous preterm birth.  
A Cochrane review and meta-analysis by Brocklehurst et al. evaluated the effect 
of antibiotic treatment of BV during pregnancy on pregnancy outcome.34 In their 
evaluation of 21 studies, investigators found that treatment of asymptomatic or 
symptomatic BV with antibiotics during gestation did not impact the rate of preterm 
birth before 37 completed weeks gestation (ARR 0.88; 95% CI 0.71-1.09; 13 trials). When 
the subgroup of women with a previous preterm birth was analyzed antibiotics were 
again shown to be ineffective in reducing rate of spontaneous premature delivery (ARR 
0.78; 95% CI 0.42-1.48; 3 trials). This review also reported that antibiotic therapy was 
often associated with side-effects that precluded women from finishing treatment. Due 
to the lack of beneficial outcome and the association between gestational antibiotic 
therapy and maternal and neonatal adverse events, the American College of 
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Obstetricians and Gynecologists and U.S. Preventive Service Task Force currently 
recommend against screening for and treating asymptomatic BV during pregnancy.24,35  
One hypothesis to explain failure of antibiotics to reduce the risk preterm birth 
associated with BV is that the extended presence of atypical microorganisms in the 
vaginal microbiome prior to antibiotic treatment cause irreversible damage. To reduce 
exposure to opportunistic or pathogenic vaginal bacteria during gestation, investigators 
explored the use of antibiotics as prophylactic agents during the interconceptional or 
gestational periods. In study of 241 women with history of spontaneous preterm birth, 
women attempting to conceive were assigned dual therapy with azithromycin and 
metronidazole or identical placebo once a month every 4 months until conception.36 
Among the 124 women who conceived during the study, there was no statistically 
significant difference in the rate of spontaneous preterm birth between the control and 
antibiotic group. Though non-statistically significant, the mean gestational age at birth 
was over 2 weeks shorter in the antibiotic group, suggesting a possible detrimental 
effect. A Cochrane review and meta-analysis published in January, 2015 evaluated the 
utility of antibiotic prophylaxis among women in their second or third trimester without 
signs of vaginal infection.37 This review, which included 7 trials and over 2,100 women, 
reported that prophylactic antibiotic administration did not reduce the rate of preterm 
delivery in the general population (ARR 0.85; 95% CI 0.64 -1.14; 5 trials) or among 
women with a previous preterm birth who were free of vaginal infection upon study 
enrollment (ARR 1.08; 95% CI 0.66-1.77; 2 trials). As a result, the use of antibiotics for 
prophylactic prevention of spontaneous preterm birth is not routine practice.  
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Although antibiotic treatment or prophylaxis against subclinical vaginal infection 
do not show meaningful reduction in infection related preterm birth, advances in the 
understanding of the vaginal microbiome provide a promising option for prevention of 
preterm birth associated with abnormal vaginal flora. Among women who experience 
uncomplicated, full-term gestations, the vaginal microbiome is steadily and almost 
exclusively colonized by Lactobacillus species, regardless of race or ethnicity.38-40 
lactobacilli bacteria and the metabolites they produce serve as physical and chemical 
barriers to the colonization and proliferation of other microbial species and contribute 
to modulation of the local inflammatory response.15,41-43 A decrease in the quantity and 
quality of the commensal vaginal lactobacilli, as is seen in BV, results in loss of a natural 
defense mechanism against inflammation and upper genital tract infection. Accordingly, 
other conditions defined by a loss of vaginal lactobacilli, such as aerobic vaginitis (AV), 
also increase risk of spontaneous preterm birth.44,45 Since a stable lactobacilli dominant 
vaginal flora is associated with full term gestation, and loss of lactobacilli underlie 
conditions associated with preterm birth, an intervention aimed at restoring the normal 
vaginal flora and preventing its deterioration may prove beneficial in reducing the 
incidence of spontaneous preterm birth due to infection/inflammation.  
Investigations dating back to the early 1990’s report the success of lactobacilli 
probiotics in preventing the development of abnormal vaginal flora and treating BV.46-48 
Due to an improved understanding of the role of commensal bacteria in human health 
and fear of increasing microbial resistance to antibiotic drugs, the use of probiotics as a 
medical therapy is a topic of great interest.49-51 Randomized controlled trials indicate 
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that lactobacilli probiotics are as effective as antibiotics in treating BV and can decrease 
the presence of non-commensal aerobic bacteria and yeast organisms in the vagina.52-57 
Lactobacilli probiotics also promote maintenance of normal vaginal flora and protect 
against relapse or future development of conditions such as BV, AV, and candidiasis, a 
prophylactic quality that antibiotics do not share.48,53-56,58 A Cochrane review and meta-
analysis including studies published prior to 2011 found an 81% decreased risk of genital 
infection with probiotic therapy during gestation (ARR 0.19; 95% CI 0.08-0.48; 2 trials).59 
This review also concluded that evidence is insufficient to determine if probiotic therapy 
during gestation impacts the incidence of preterm birth or associated complications. A 
review of the literature published in February, 2015 spoke to the physiological basis and 
therapeutic potential of probiotics to reduce the incidence of preterm birth, but also 
concluded that evidence from clinical trials is significantly limited.49 Since lactobacilli 
probiotics are deemed safe for use during pregnancy, and their use is not associated 
with significant side-effects or adverse events when taken orally or intravaginally, this 
intervention deserves further investigation as a means to reduce preterm birth.49,60,61  
1.2 STATEMENT OF THE PROBLEM 
Preterm birth is the leading cause of neonatal morbidity and mortality. Most 
preterm births are not medically indicated and women with a history of spontaneous 
preterm birth are at a high risk for spontaneous preterm birth in a subsequent 
pregnancy. A significant proportion of spontaneous preterm births in this high-risk 
population are attributed to subclinical infection and inflammation arising from 
dysbiosis of the vaginal flora. Evidence suggests that lactobacilli probiotics are able to 
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prevent the development of abnormal vaginal flora and treat dysbiotic conditions that 
are associated with increased risk of preterm delivery. Despite the possible utility of 
probiotics in preventing preterm birth, a randomized, placebo-controlled trial of 
prenatal intravaginal probiotic supplementation among women at high risk for 
spontaneous preterm birth has not been conducted.    
1.3 GOAL AND OBJECTIVES 
 The goal of this proposal is to identify an intervention that can effectively reduce 
the incidence of spontaneous preterm birth. The proposed study will determine if daily 
intravaginal lactobacilli probiotic supplementation, beginning in the late first or very 
early second trimester, reduces the incidence of spontaneous preterm birth prior to 37 
completed weeks gestation among high-risk women. The study will also monitor the 
incidence of neonatal and maternal complications associated with preterm delivery to 
determine if probiotics reduces the short-term sequelae of prematurity. This study will 
also involve the collection of vaginal flora samples during gestation for future analysis of 
the impact of probiotic therapy on the evolution of the vaginal microbiome. 
1.4 HYPOTHESIS 
In pregnant women with a history of spontaneous preterm birth, there will be a 
difference in the incidence of recurrent spontaneous preterm at <37 weeks completed 
gestation in patients treated with an intravaginal probiotic containing Lactobacillus 
brevis CD2, Lactobacillus salivarius subspecies salicinius FV2, and Lactobacillus 
plantarum FV9 daily from 10-14 completed weeks gestation until delivery in comparison 
to patients treated with an identical course of an intravaginal placebo. 
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CHAPTER 2: LITERATURE REVIEW 
2.0. INTRODUCTION   
Multiple searches of the PubMed database, Ovid MEDLINE and EMBASE 
databases, and Cochrane Library were conducted between June, 2014 and June, 2015. 
Terms used to search for relevant literature included combinations of the following; 
vaginal microbiome, vaginal micorbiota, vaginal flora, abnormal vaginal flora, bacterial 
vaginosis, intermediate flora, aerobic vaginitis, pregnancy, preterm birth, premature 
labor, probiotic, lactobacilli, and lactobacillus. Results were filtered for English language 
articles and evaluated for theoretical soundness, strength of methodology, and 
significance of reported outcomes. The cited references of available articles were also 
evaluated to ensure that all pertinent publications were obtained. Relevant articles 
were further analyzed and included in this review.  
CHAPTER 2 PART 1: REVIEW OF RELEVANT LITERATURE 
2.1. DYNAMICS OF THE VAGINAL MICROBIOME  
 An understanding of the composition of the vaginal microbiome during states of 
health is necessary to recognize microbial changes associated with disease. The 
following section focuses on the dynamics of the vaginal microbiome prior to menarche 
and throughout the reproductive years. Special attention will be given to the 
composition of the vaginal microbiome during healthy, full-term pregnancy. 
2.1a The Vaginal Microbiome Prior To Menarche 
 Published research pertaining to the composition of the vaginal microbiome 
prior to and during puberty is sparse. Existing evidence suggests that the composition of 
 15 
the vaginal microbiome among healthy females is heterogeneous prior to puberty, 
becoming less diverse and more similar to that of reproductive age females as 
menarche approaches. Results of three unassociated cross-sectional studies comparing 
the vaginal microbiome of pre-pubescent females with vulvovaginitis to that of healthy 
controls indicate that the most common dominant bacteria in the microbiomes of 
controls were aerobic Staphylococcus epidermidis, Escherichia (E.) coli, Enterococcus, 
and Streptococcus viridans.1-3 Two of the investigations also noted exclusive domination 
or co-domination by the anaerobes Peptostreptococcus or Peptococcus.2,3 Lactobacillus, 
the most common dominant species in the microbiome of reproductive age females, 
was rarely cultured from healthy girls.2 The results of the investigations are consistent 
with the relatively high vaginal pH of 6.0-7.0 measured in pre-pubertal females, which 
reflects a paucity of lactic acid fermenting species such as Lactobacillus.4 
The diversely colonized, pH neutral vaginal microbiome of prepubescent females 
transitions to a more uniform, acidic environment by the time of menarche. In a 2-year 
longitudinal investigation, weekly vaginal swabs were collected for gram stain analysis 
among never sexually active 13-18 year old Ugandan females.5 Premenarchal females, 
those who did not experience menarche during the 2-year period, began the study 
without gram stain evidence of lactobacilli on vaginal swab. However, these females 
exhibited a significant (p<0.05) weekly increase in the proportion of lactobacilli on gram 
stain and a significant decline (p<0.05) in other morphotypes.5 In contrast, participants 
who achieved menarche during or prior to the 2-year time frame began the study with 
significantly (p=0.002) more lactobacilli on gram stain and did not exhibit a significant 
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change in proportion of morphotypes. The transformation of the microbiome of 
premenarchal females was likely due to a rise in circulating estrogen and subsequent 
glycogen deposition in the vaginal epithelium, which occurs during the onset and 
progression of puberty.5,6 Glycogen serves as a nutrient source for lactobacilli bacteria 
and abundance of this polysaccharide favors proliferation of Lactobacillus species.6 
2.1b The Vaginal Microbiome During The Reproductive Years 
According to criteria established in 1991 by Nugent et al., the normal vaginal 
microbiome of reproductive-age women is characterized by a pH of <4.5 and dominant 
colonization by Lactobacillus species.7 Lactobacilli are facultative anaerobic gram-
positive rods that contribute to the acidification of the vaginal environment by 
fermenting glycogen to lactic acid. The advent of technology allowing for culture 
independent analysis of the vaginal microbiome recently corroborated the long-
standing criteria established by Nugent. Culture independent 16S rRNA amplification 
and sequencing studies demonstrate that the vaginal flora of 73-80% of healthy North 
American women is dominated by Lactobacillus (L.) crispatus, L. gasseri, L. iners, or L. 
jensenii.8-11 Multiple proportionally small communities of opportunistic bacteria also 
exist within the lactobacilli dominant vaginal microbiomes and consist of strict 
anaerobes such as Gardnerella, Sneathia, Atopobium Megasphaera, Peptoniphilus, 
Dialister, and Prevotella, which are commonly associated with bacterial vaginosis.8,9  
Due to similarities between the vaginal microbiomes of reproductive age females 
it is possible to classify fertile microbiomes into one of five groups, which reflect the 
dominant inhabitant(s) of the vaginal flora. Microbial community state types (CSTs) I, II, 
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III, & V are respectively dominated by L. crispatus, L. gasseri, L. iners, and L. jensenii, 
while CST IV is populated by a mixed community of strict anaerobes.8,10,11 As previously 
noted, CSTs I-III and V represent the majority of the population. However, significant 
differences are observed in the prevalence of CSTs based on race and ethnicity. Cross-
sectional analyses suggest that over 30% of healthy, asymptomatic Hispanic and black 
women possess a CST IV vaginal flora dominated by strict anaerobes, while this CST is 
only observed in 8-9% of Caucasian females.8,9 The variance in CST IV representation 
between Hispanic/black and Caucasian/Asian women remains significant (p<0.0001) 
when controlling for socioeconomic and behavioral variables.9  
In addition to differences between ethnicities, longitudinal studies demonstrate 
that the vaginal microbiome of individual women transiently fluctuate between CSTs.11-
13 A 16-week study of 32 healthy women utilized biweekly mid-vaginal swab and culture 
independent16s rRNA sequencing to track the variability of CSTs in the microbiome of 
each enrolled woman.11 This investigation found women predominantly colonized by L. 
crispatus (CST I) or L. gasseri (CST II) at baseline possessed a relatively stable 
microbiome that infrequently fluctuated, while women with a L. iners (CST III) dominant 
flora at baseline were more likely to experience frequent fluctuations. 
Some investigations suggest that variations in the microbial composition of the 
vaginal microbiome are due to menstruation.11,12 However, this claim was disputed by a 
recent study of 27 healthy, asymptomatic women during a single menstrual cycle.13 In 
this longitudinal observational study, vaginal swabs were collected at 4 time points 
during menstruation and the microbial composition of the vaginal microbiome at each 
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time was determined by culture-independent gene sequencing. Overall, 23% of women 
experienced transient shifts in their microbiome during the menstrual cycle, however no 
correlation between CST fluctuation and time point in menstruation was detected.  
2.1c The Vaginal Microbiome During Pregnancy 
The vaginal microbiome of pregnant women who experience uncomplicated, full 
term pregnancies is distinctly different from that of non-pregnant reproductive age 
women. During healthy gestation the vaginal microbiome becomes less diverse, 
exhibiting almost exclusive dominance by Lactobacillus spp. and a significant decrease in 
cohabitation by additional phylotypes. In a prospective case-controlled study, Romero 
et al. compared the vaginal microbiome of 22 pregnant women with uncomplicated full 
term gestations to that of 32 healthy non-pregnant controls.10 Vaginal swabs were 
collected over 16 weeks and vaginal microbial composition was determined via culture-
independent 16s rRNA pyrosequencing. After adjusting for false discovery rate, a 2-5.5 
fold increase in L. crispatus, L. gasseri, L. jensenii, L. vaginalis (p<0.02) and a 2-355 fold 
decrease in 21 other phylotypes (p<0.02) was observed among pregnant women when 
compared to controls. Though the results of this investigation suggest a significant 
transformation in the vaginal microbiome during gestation, interpretation and 
generalization of findings are limited by a significant difference in the racial profile of 
cases and controls. While the pregnant cohort consisted of 86% black and 10% white 
women, the control cohort was populated by 50% black and 40% white women. To 
address the demographic limitations of this study, results from this assessment were 
aggregated with findings from a second culture-independent 16s rRNA study of the 
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vaginal flora during pregnancy.14 The second study assessed the composition of the 
vaginal microbiome during each trimester and only enrolled Caucasian participants. 
Using the Chao1 diversity index to compare the microbiome of pregnant black and 
white women to non-pregnant counterparts a significant decrease in the diversity of the 
vaginal flora was observed in both races (p<0.01) and there was no significant difference 
between the frequencies of CSTs between pregnant black and white women. This 
finding is particularly crucial as it displays that pregnancy eliminates the racial disparity 
in lactobacilli dominated vaginal flora.  
Another significant change in the vaginal microbiome of women with full-term 
gestations is the development of a more stable microbial community that is resistant to 
transient fluctuations in CST. In the aforementioned study by Romero et al., the log 
Jensen-Shannon distance was 1.6 fold lower in the pregnant cohort, indicating 
significantly fewer fluctuations in bacterial composition and greater stability in the 
vaginal microbiome (p<0.001). Furthermore, only 5.8% (8/139) of vaginal samples from 
pregnant women in comparison to 38.5% (296/761) of samples from non-pregnant 
controls represented an anaerobic dominant flora. In comparison to non-pregnant 
women, the odds of observing vaginal flora dominated by anaerobes associated with 
bacterial vaginosis were 95% lower among pregnant women (OR: 0.047; p<0.00001).  
 In conclusion, the overall trend of the vaginal microbiome from childhood to the 
childbearing years is towards Lactobacilli dominance and increasing stability. The 
maintenance of a lactobacilli dense, stable vaginal flora during gestation appears to be 
of evolutionary benefit as its development spans races and ethnicities. The previous 
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section described the state of the vaginal microbiome during times of health, including 
the progression of full-term pregnancy. The following sections will detail the deleterious 
impact of abnormal vaginal flora on pregnancy and describe evidence supporting the 
use of probiotics to prevent preterm birth associated with abnormal flora.  
2.2. ASSOCIATION BETWEEN ASYMPTOMATIC ABNORMALITIES OF THE VAGINAL 
FLORA AND SPONTANEOUS PRETERM BIRTH  
Evidence suggests that disruption in the evolution of the normal vaginal 
microbiome during pregnancy places women at an increased risk for experiencing 
spontaneous preterm delivery. In this section the evidence supporting an association 
between asymptomatic deficiencies in the normal lactobacilli composition of the vaginal 
microbiota and spontaneous preterm birth will be reviewed.  
2.2a Asymptomatic Bacterial Vaginosis and Spontaneous Preterm Birth 
Bacterial vaginosis (BV), a condition characterized by a marked increase in 
anaerobic bacteria and decrease in vaginal lactobacilli, affects 20-30% of pregnant 
women and half of the cases are asymptomatic.9,15 The positive correlation between 
symptomatic BV and spontaneous preterm birth is well researched, and the impact of 
asymptomatic BV on risk of prematurity is gaining recognition.  In 2005, Klebanoff et al. 
published an analysis of data from 12,937 women enrolled in the Maternal-Fetal 
Medicine Units Network’s clinical trials on BV and Trichomonas vaginalis.16 Investigators 
compared birth outcome among 4,634 asymptomatic women with BV, who received no 
intervention, to 8,303 asymptomatic women without BV per Nugent criteria.7 Women 
were initially screened for BV at 8-12 weeks gestation and rescreened every 2 weeks 
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until 21-22 weeks gestation. The rate of spontaneous preterm birth at <38 weeks was 
significantly higher among women with asymptomatic BV than among women without 
BV (15.1% vs. 12.1%; p<0.001). Congruently, a systematic review and meta-analysis of 
32 studies published between 1990 and 2005 concluded that asymptomatic BV doubles 
the risk of spontaneous preterm birth (OR 2.16; 95% CI 1.55-3.0) and increases odds of 
miscarriage at 14-24 weeks by 6-fold (OR 6.32; 95% CI 3.65-10.49).17 The preceding 
studies also found that women diagnosed with BV in the late first trimester were at 
similar risk of preterm birth as those diagnosed in the second or third trimester.16,17 
2.2b Asymptomatic Aerobic Vaginitis and Spontaneous Preterm Birth 
In 2002 Donders et al. defined a type of abnormal vaginal flora different from 
BV.18 This clinical entity, termed aerobic vaginitis (AV), is a condition of vaginal microbial 
dominance by enteric aerobes with resultant signs of local inflammation and research 
suggests an association between an asymptomatic AV and preterm birth.19 A 
prospective cohort study of 759 pregnant women determined that females with 
asymptomatic AV at <16 weeks gestation were more likely to experience preterm 
delivery at <35 weeks gestation (OR 3.2; 95% CI 1.2–9.1; p=0.038) and pregnancy loss at 
<25 weeks gestation (OR 5.2; 95% CI 1.5–17; p=0.019) when compared to controls.20 An 
additional study of the vaginal microbiome in late pregnancy found similar adverse 
effects associated with AV. In a longitudinal cohort study 2,828 pregnant women were 
screened at 23-26 weeks gestation and again at parturition.21 In a stepwise regression 
analysis, which controlled for factors such as age, race, parity, heavy growth of the 
aerobes Klebsiella pneumoniae and E. coli between first screen and delivery resulted in a 
 22 
3-fold increase in odds of delivery at <37 weeks gestation (AOR 2.99; 95% CI 1.37-6.53; 
p<0.05). These studies suggest that an abnormal vaginal flora dominated by aerobes is a 
risk factor for preterm birth regardless of when it is present during gestation.  
2.2c Lactobacilli Vaginal Flora and Spontaneous Preterm Birth  
In addition to asymptomatic BV and AV, more subtle asymptomatic alterations in 
the vaginal microbiome are noted as possible predictors of spontaneous preterm birth. 
Novel evidence suggests that women with a vaginal microbiome dominated by certain 
species of lactobacilli may be at an increased risk for suboptimal pregnancy outcome, 
despite a lack of clinical or gram stain evidence of vaginal microbial abnormality. A 
prospective cohort study published in 2014 found that the solitary presence of L. iners in 
the vaginal microbiome was associated with a increased rate of preterm birth.22 Among 
111 women with normal vaginal flora (Nugent 0-3) at 11-14 weeks gestation, 16% 
(16/98) of women who delivered at term were colonized by L. iners alone, while 85% of 
women (11/13) with spontaneous preterm birth were solely colonized by this organism 
(p=0.001). In accordance with these findings, a prospective cohort study found that 
pregnant women without L. iners as the dominant Lactobacillus species in their 
cervicovaginal fluid at 20-24 and 24-28 weeks gestation were significantly more likely to 
deliver at term than women with L. iners dominance (68% vs. 39%, p<0.002).23  
 The aforementioned conditions represent states of insufficient lactobacilli 
quantity or quality. The association between preterm birth and asymptomatic BV and 
AV is most likely explained by an increase in local and systemic inflammation and 
compromise of the cervicovaginal mucosal barrier.24-26 When the vaginal microbiome is 
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predominated by non-Lactobacillus species pro-inflammatory cytokines increase, anti-
inflammatory cytokines decrease, and enzymes capable of degrading the cervical mucus 
plug are found in higher concentrations.27 The mechanism by which a L. iners dominant 
microbiome influences risk for preterm birth appears to be similar to that of other 
vaginal infections. Witkin and colleagues found that unlike L. crispatus, L. gasseri and L. 
jensenii, L. iners is not capable of producing significant amounts of d-lactic acid.6 A 
decrease in the proportion of d-lactic acid in the vaginal microbiome results in a cascade 
of events leading to an increased production of matrix metalloproteinase, an enzyme 
that degrades the extracellular matrix of the endocervical epithelial barrier. Vaginal 
epithelial cell inoculation with L. iners is also shown to significantly increase the 
expression of genes encoding for tumor necrosis factor alpha, a pro-inflammatory 
cytokine, and genes encoding for antimicrobial peptides.28 Similar results are not found 
with L. crispatus inoculation.  
2.3 ROLE OF PROBIOTICS IN PREVENTION OF SPONTANEOUS PRETERM BIRTH  
An increased incidence of preterm birth is associated with asymptomatic 
abnormalities in the quantity or quality of Lactobacillus species within the vaginal 
microbiome. A versatile intervention capable of preventing and normalizing dysbiotic 
vaginal flora must be identified to reduce the burden of preterm delivery among 
affected women. In this section of the literature review clinical trials that assessed the 
use of probiotics in treating and preventing abnormalities of the vaginal flora among 
reproductive age women will be evaluated. Preliminary data regarding the impact of 
probiotic supplementation on length of gestation will also be described. Probiotics are 
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live microorganisms that confer health benefits when taken in sufficient amounts and 
their use in modern medicine is increasing with better understanding of the human 
microbiome.29 Since probiotics are shown to be safe and well tolerated during 
pregnancy, their efficacy in stabilizing the vaginal microbiome could prove valuable in 
reducing infection and inflammation related preterm birth.30,31 
2.3a Probiotics and the Treatment or Prevention of Abnormal Vaginal Flora 
 Randomized, controlled trials investigating the effectiveness of probiotics in 
maintaining or reestablishing a normal vaginal flora among non-pregnant, reproductive 
age women suggest a promising role for probiotic therapy in promoting vaginal health. 
In 2003, Reid and colleagues performed a randomized, double blind, placebo-controlled 
trial that enrolled 64 reproductive age women without symptoms of vaginal infection.32 
Women were assigned to a 60-day course of a once daily oral probiotic capsule 
containing 109 colony-forming units (CFUs) of L. rhamnosus GR-1 and L. reuteri RC-14 or 
an identical calcium carbonate placebo capsule. In comparison to baseline, the number 
of lactobacilli cultured from vaginal swabs of women receiving probiotic increased by 
log 10 on day 28 (p = 0.01), while no significant increase was observed in the placebo 
group. Day 28 vaginal samples also revealed a significant decrease in vaginal yeast 
organisms (p = 0.01) and coliform bacteria (p = 0.001) among probiotic participants in 
comparison to controls. These findings suggest a role for oral lactobacilli probiotics in 
promotion of  vaginal lactobacilli richness and inhibition of vaginal opportunist or 
pathogen proliferation. Accordingly, of the women who began the above study with a 
normal vaginal flora per Nugent criteria, those who were assigned probiotic maintained 
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a normal flora at 28 and 60 day follow-ups, while 23% and 16% of women assigned 
placebo were diagnosed with BV at 28 and 60 days, respectively (p<0.05).7 Of note, 
significant changes in lactobacilli counts were not observed in the probiotic or placebo 
group on day 7 of treatment, indicating a lag time for the onset of effect. 
 In a follow-up investigation, Reid and colleagues demonstrated that a 60 day 
course of the same formulation of oral probiotic was able to reestablish a normal 
vaginal flora among women diagnosed with BV.33 At enrollment 8 of 29 women (28%) in 
the probiotic arm and 7 of 30 women (23%) in the placebo arm were diagnosed with 
asymptomatic BV according to Nugent criteria.7 After completion of treatment all 7 
women in the placebo group remained BV positive, while only one woman who received 
probiotic intervention failed to convert to normal vaginal flora (p<0.008). Vaginal flora 
were only evaluated at baseline and upon the completion of probiotic therapy, making it 
impossible to assess the rate of flora normalization in this trial. Results from these 
randomized studies suggest that oral administration of 109 CFUs of L. rhamnosus GR-1 
and L. reuteri RC-14 is capable of enriching, maintaining, and reestablishing the normal 
vaginal microbiome of reproductive age women. However, it may take up to 2 months 
for these beneficial effects of oral probiotics to be achieved.  
 An alternate route for delivery of lactobacilli probiotics is direct application to 
the vaginal environment via vaginal suppository. Evidence suggests that this method of 
application may decrease time needed for improvement or enrichment of vaginal flora. 
A randomized, double blind, placebo-controlled trial recently investigated the use of an 
intravaginal probiotic containing 109 CFUs L. brevis CD2, L. salivarius salicinius FV2, and 
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L. plantarum FV9 in the treatment or prevention of BV.34 In this study, 34 reproductive 
age women with a history of recurrent BV and a current BV diagnosis (Nugent >7) were 
randomized to 7-day course of probiotic or placebo.7 Upon completion of therapy, 
significantly more women in the probiotic group were free of BV in comparison to 
controls (p<0.001). At 7-day follow-up each of the 18 women randomized to receive 
probiotic were free of BV, as 83% had normal vaginal flora (Nugent <3) and 17% had 
intermediate flora (Nugent 4-6).7 However, none of the 16 women randomized to 
placebo developed normal flora by day 7 and only 2 women had intermediate flora. A 2-
week post-treatment assessment revealed that 61% of women who received probiotic 
remained BV free, while only 19% who received placebo were free of BV (p=0.017). 
 Results from a second randomized, double blind, placebo-controlled trial of the 
same intravaginal probiotic formulation also indicated a significant benefit.35 In this 
study, 148 reproductive age women with BV, intermediate flora, or normal vaginal flora 
were randomized via a computer generated sequence to an 8-day course of once daily 
intravaginal probiotic or a tablet containing pH-lowering compounds. Among women 
who began the study with BV or intermediate flora, a significant rate of conversion to 
normal vaginal flora (Nugent <3) was observed in the probiotic (p=0.007) but not 
placebo group. At the completion of treatment, 80% of women in the probiotic arm who 
began the study with abnormal flora were cured of BV (Nugent <7) and 65% possessed 
normal flora (Nugent <3).7 In addition, 97% of women in the probiotic group who began 
the study with normal flora maintained normalcy following treatment, while only 68% of 
controls had normal vaginal flora at follow-up (p=0.014). Investigators also found a 
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reduction in the concentration of the pro-inflammatory cytokines interleukin-1, beta 
(p<0.001) and interleukin-6 (p<0.015) within the cervicovaginal fluid of women treated 
with probiotics, while no significant change was noted among women given pH tablets.  
 The effectiveness of intravaginal probiotics was also compared to intravaginal 
antibiotics in the treatment and prevention of abnormal vaginal flora. In a non-blinded 
clinical trial Ling et al. randomized 25 women with BV to a 10-day course of a daily 
intravaginal probiotic containing 109 CFUs L. delbrueckii lactis DM8909 and 30 women to 
a 7-day course of a daily 500mg metronidazole vaginal suppository.36 Probiotic was 
found to be as effective as metronidazole in eradicating BV after 5 days of treatment, 
with 88% of women in the probiotic groups and 83% of women in the metronidazole 
group possessing a Nugent score <3 (p=0.635).7 Probiotic was significantly more 
effective in maintaining a BV free state after completion of therapy as 96% of women in 
the probiotic group had normal vaginal flora (Nugent <3) at 30 days follow-up in 
comparison to 70% in the metronidazole group (p=0.013).7 In addition, 20% of women 
in the metronidazole arm who were cured of BV at day 5 relapsed at day 30, while 
relapse was not observed in the probiotic group. Culture independent pyrosequencing 
of bacterial organisms sampled from the vagina revealed that women cured with 
probiotic regained a rich microflora dominated by L. crispatus, yet women cured with 
metronidazole were more likely to harbor sparse flora dominated by L. iners.   
 In a single-blind comparative clinical trial, Anukam and colleagues reported 
superior BV cure rates among women randomized to a 5-day course of an intravaginal 
probiotic containing 109 CFUs of L. rhamnosus GR-1 and L. reuteri RC-14 compared to 
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those receiving a 5-day course of 0.75% metronidazole gel.37 According to a per-
protocol analysis, women assigned to probiotic experienced cure rates of 80%, 85%, and 
90% at 6, 15, and 30 days follow-up respectively, while only 45%, 45%, and 50% of 
women in the control arm were BV negative at respective follow-up intervals. All 
subjects returned for 5 and 15 day reassessments but 10% of women in the probiotic 
group and 15% in the metronidazole group were lost to follow-up at 30 days. It is 
possible that attrition bias impacted the results of this analysis, but since loss-to-follow-
up rates were similar in both populations it is unlikely that the overall study conclusion 
would differ significantly. Notably, BV cure was defined as a Nugent score <7 in this trial, 
thus including women with intermediate vaginal flora in the cure category.7 At each 
follow-up approximately 40% of women cured of BV in the probiotic group possessed 
intermediate vaginal flora. In comparing results from this trial to results from Ling et al., 
it appears that a longer course (10 days vs. 5 days) of probiotic therapy may be more 
beneficial for complete normalization of vaginal flora.  
 Clinical trials assessing the utility of probiotics for the prevention or treatment of 
abnormal vaginal flora among pregnant women are limited. However, available data 
suggest that probiotics are similarly effective in treating and preventing abnormal 
vaginal flora among pregnant and non-pregnant women. A double blind, placebo-
controlled trial published in 1996 randomized a group of pregnant and non-pregnant 
premenopausal women with BV or intermediate flora to a 6-day course of intravaginal 
probiotic capsule containing 107 CFUs L. acidophilus and 0.03mg estriol or a placebo 
suppository.38 The probiotic group consisted of 11 non-pregnant and 6 pregnant women 
 29 
and the control group comprised 13 non-pregnant and 2 pregnant participants. BV was 
diagnosed according to Amsel criteria.39 Pregnant and menstruating women were 
instructed to apply two capsules daily, while non-pregnant, non-menstruating females 
applied one capsule per day. An intragroup analysis of microbiological and clinical at 15 
and 28 days after the start of therapy reveled no difference between women receiving 
one or two capsules, thereby investigators aggregated results from women receiving 
different daily dosages within each group for final analyses. At 15 and 28 days post-
enrollment 77% and 88% of women in the probiotic arm were cured, while only 25% 
and 22% were cured in the placebo group, respectively (p<0.05). Significantly more 
women in the probiotic group had >30 lactobacilli per high power field on vaginal swab 
culture at 30 day follow-up than women in the placebo group (88% vs. 12%, p<0.05). 
Though sample size was small in this investigation, the similar outcomes among non-
pregnant and pregnant women receiving the same probiotic formulation suggests 
generalizability of results from studies in non-pregnant women to pregnant women.  
 In another investigation of probiotics among pregnant women, researchers 
assessed the utility of commercially available food items containing active lactobacilli 
cultures to establish or maintain normal vaginal flora. In this randomized clinical trial, 
Neri et al. enrolled 84 women with symptomatic BV based on Amsel criteria during the 
first trimester.39,40 Women were randomized to receive 2 weeks of twice daily 
intravaginal yogurt containing 109 CFUs L. acidophilus, 2 weeks of twice daily insertion of 
a tampon soaked in 5% acetic acid, or no intervention. Vaginal swabs were repeated 4 
and 8 weeks after therapy. At both time points 88% of women receiving probiotics and 
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38% of women receiving acetic acid were BV negative (88% vs. 38%, p<0.04). Women 
receiving no intervention had the lowest rate of vaginal flora normalization during 
follow-up, with only 15% and 5% of women BV free at 4 and 8 weeks, respectively (88% 
vs. 15%, p<0.0005; 88% vs. 5%, p<0.0005).  Though results of this study promote the 
utility of probiotics, lack of blinding introduces risk of observer bias and undermines the 
strength of the positive association.  
 In an understanding of the link between abnormal vaginal flora and spontaneous 
preterm birth, Stojanovic and colleagues composed a prospective observational trial 
aimed at assessing the effect of probiotic supplementation on parameters predictive of 
pregnancy progression in addition to vaginal flora state.41 In this randomized, non-
blinded, controlled trial, a cohort of 60 women were enrolled at 16-22 weeks gestation 
and allocated to receive an intravaginal probiotic containing 106 CFUs L. rhamnosus 
BMX54 once weekly for 12 weeks or no intervention. A thorough gynecologic exam was 
performed at enrollment and once every 4 weeks during the 12 week study. Upon 
enrollment 36% of women in the control group and 13% of women allocated probiotic 
had abnormal flora typified by the presence of Candida albicans, E. coli, Enterococcus, 
and/or beta-hemolytic Streptococcus on vaginal swab culture (36% vs. 13%, p=0.0716). 
At week 12 follow-up only 1 woman in the probiotic group had abnormal vaginal flora 
and this participant was one of the 4 with pathogenic presence on enrollment. However, 
of 55% the untreated women who possessed abnormal flora on enrollment maintained 
abnormal flora at 12 week follow-up and 58% of controls who had normal flora on 
enrollment converted to abnormal flora by the last assessment. Thus, there was a 
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significant trend towards altered vaginal flora in the control but not probiotic group 
during the 12-week study (χ² for trend: p=0.041 vs. p=0.163). In addition, one way 
ANOVA for repeated measures and post-test for trend analyses revealed significant 
trends for greater cervical dilation (p=0.0381) and lower position of the fetal head 
(p<0.0001) among women in the placebo but not probiotic group. Comparing between 
groups, the centimeter cervical dilation at 12 weeks was significantly greater among 
women in the untreated arm (0.37cm + 0.54 vs. 0.05cm + 0.27; p<0.01) and the fetal 
head was significantly more descended beyond the interspinous line in untreated 
women (2.83 + 1.51 vs. 3.80 + 0.76; p<0.01). Though this study was not blinded, 
introducing increased opportunity for bias, these results provide interesting insight to 
potential physiologic mechanisms of gestation prolongation due to the presence of a 
lactobacilli enriched vaginal microbiome. 
2.3b Probiotic Supplementation and Spontaneous Preterm Birth 
 Overall, the literature suggests a beneficial role for lactobacilli probiotics in 
enriching, maintaining, and/or normalizing the vaginal microbiome. Some studies also 
imply that lactobacilli probiotics can decrease inflammatory cytokines and exert some 
protective impact against the premature progression of gestation.35,41 Despite a 
potential role for probiotics in decreasing risk of spontaneous preterm birth through 
prevention of abnormal vaginal flora, very few existent studies assess the relationship 
between gestational probiotics supplementation and incidence of prematurity. In one 
randomized clinical trial, investigators aimed to assess the relationship between dietary 
counseling, oral probiotic supplementation, and the incidence of gestational diabetes.42 
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As a secondary outcome investigators analyzed the incidence of preterm delivery 
between probiotic and control participants. Women were randomized in their first 
trimester to receive intensive dietary counseling and a daily oral probiotic containing 
1010 CFUs L. rhamnosus GG and Bifidobacterium (B.) lactis Bb12, dietary counseling and 
placebo, or placebo alone. There was no statistically significant difference in incidence 
of preterm birth between groups. However, only 4 of the 191 (1.7%) participants 
experienced spontaneous preterm delivery and a prior study by Reid and colleagues 
found that, unlike L. rhamnosus GR-1 and L. reuteri RC-14, L. rhamnosus GG does not 
effectively colonize the vagina when taken orally.32 Since incidence of preterm birth was 
so rare in this cohort and the probiotic supplement does not have known ability to 
colonize the vaginal microbiome, results from this study do not offer meaningful 
information on the association between probiotic supplementation and preterm birth.  
 A randomized, double blind, parallel group clinical trial also included incidence of 
spontaneous preterm birth as a secondary outcome in their study of probiotic therapy 
during pregnancy. The primary outcome of this study was rate of BV cure following 1 
week of treatment with 300mg oral clindamycin twice daily or once daily treatment with 
an oral probiotic yogurt containing L. bulgaris, Streptococcus thermophilus, and B. lactis. 
Participants included 300 pregnant women at 34-37 weeks gestation with BV according 
to Amsel criteria.39 Women were excluded from the study if they had a history of 
spontaneous preterm birth in a prior gestation. Investigators found that probiotic was as 
effective as clindamycin in curing BV following 7 days of treatment, with an 80% cure 
rate in the probiotic group and 84% cure rate in the antibiotic group. Investigators also 
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reported no significant difference between the incidence of spontaneous preterm birth 
between women receiving probiotic or antibiotic (14% vs. 8%, non-significant). These 
preterm birth results are difficult to interpret as a control population of similar women 
treated with a placebo was not included. It is unknown if probiotic and clindamycin both 
exerted no effect on preterm birth rate or if both were associated with an increased or 
decreased rate. Furthermore, some of the enrolled women were already at full-term 
gestation upon enrollment, making statistical analysis of incidence of preterm birth 
between the groups unreasonable.  
 Incidence of preterm birth in relation to probiotic supplementation during 
gestation was the primary outcome of two recently published investigations, yet one of 
these trials was underpowered and failed to provide results (sect. 2.6).43 The adequately 
powered investigation, conducted by Myhre et al. was a case-control study that 
assessed intake of probiotic foods during gestation among cases who had spontaneous 
preterm deliveries at >22 and <37 completed weeks gestation and controls with full-
term deliveries at 38 to <41 completed weeks. Cases and controls were selected from a 
cohort of over 100,000 women who participated in the Norwegian Mother and Child 
Cohort Study. As a component of this study women completed a validated food 
frequency questionnaire at 17-22 weeks gestation that specifically assessed intake of 
multiple foods including “Biola” or “Cultura,” which are milk/yogurt products containing 
L. acidophilus LA-5, B. lactis Bb12, and L. rhamnosus.44 A total of 950 cases and 17,938 
controls were included in the final analysis. Results of a multiple logistic regression 
indicated that high intake of probiotics food, equivalent to 2.85x109-2x1011 probiotic 
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organisms per day, was associated with a significant 18% decrease in the odds of 
spontaneous preterm birth (AOR: 0.820; 95% CI: 0.681-0.986, p=0.035). Though this 
experiment followed a retrospective design and does not provide the same level of 
evidence as a randomized clinical trial, the use of methods to reduce risk of bias and 
confounding give significant weight to the study results. 
 In the above investigation, Myhre et al. controlled for selection bias by sampling 
a large cohort of controls from the same base population that cases were selected from 
and reduced risk of recall bias by using information from a validated questionnaire 
distributed during gestation.  Bias from misclassification of cases was avoided by the 
application of strict exclusion criteria that eliminated women from the study if they 
experienced non-spontaneous preterm birth. Women with preterm delivery were 
excluded as cases if they had preexisting medical conditions prior to gestation, such as 
thromboembolic disease or diabetes, or if their pregnancy was complicated by 
conditions such as preeclampsia or placenta previa. Confounding was controlled for 
through binary and multiple logistic regression analyses. Variables included in the final 
multiple logistic regression were those associated with probiotic food exposure (p<0.05) 
and outcome in the binary logistic analysis (p<0.10) and included parity, physical 
activity, and maternal educational level. The outcome and rigorous methodology of this 
study provides meaningful support for probiotics in prematurity prevention.  
2.4 CONCLUSION: REVIEW OF RELEVANT LITERATURE 
The vaginal microbiome is dynamic throughout the female lifecycle and 
undergoes unique changes during gestation. Evolution of a stable, Lactobacillus 
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dominant vaginal microbiome during pregnancy is associated with healthy full-term 
gestation, while vaginal flora abnormalities defined by a decrease in quantity or quality 
of vaginal lactobacilli are associated with an increased risk for spontaneous preterm 
birth. Efficient treatment and effective prevention of asymptomatic abnormalities of the 
vaginal flora associated with preterm birth is possible through intravaginal treatment 
with probiotics containing specific species of lactobacilli. However, a randomized, 
placebo-controlled trial of intravaginal probiotic supplementation among women at 
high risk for spontaneous preterm delivery has not been conducted.  
CHAPTER 2 PART 2: METHODOLOGICAL CONSIDERATIONS 
2.5 STUDY DESIGN 
The proposed study will be a randomized, double blind, placebo-controlled trial. 
To ensure strength in study design, the proposed investigation will adhere to the 
rigorous precedent set by Hemalatha et al. in their randomized, double blind, placebo-
controlled trial of intravaginal probiotics (sect. 2.3a).35 In their investigation women 
were randomized to study arms by a computer generated randomization list, allocation 
was concealed using a sealed envelope, and an uninvolved third party maintained the 
randomization list and distributed the envelopes. Study participants and personnel, 
outcome observers, and health-care providers were blinded to intervention allocation 
and probiotic and placebo were identical in appearance and dosing.  
A nationwide multicenter design will also be utilized to ensure an adequate 
number of participants and increase the generalizability of study results. As the sample 
size calculation indicates (sect. 2.8), a total of 1,172 women will be needed to power this 
 36 
study when accounting for a 10% attrition rate. A total of 15 academic medical centers 
that average 5,000 births per year will be included as participating sites. Since the 
national incidence of singleton preterm birth is 9.7% and 75% of preterm births are 
spontaneous, approximately 7.3% of women delivering at hospitals across the United 
States meet inclusion criteria with a history of singleton spontaneous preterm birth.45,46 
Considering a recruitment duration of 14.5 months and an average yearly delivery rate 
of 5,000 infants at each site, an average of 440 women at each location will meet 
inclusion criteria during the study. In their multicenter trial of progesterone therapy in 
American women with a history of spontaneous preterm birth, Meis et al. reported that 
45% of women who met all study criteria consented to study participation.47 To account 
for failure in identification or recruitment of all eligible women at each study site and to 
account for losses to enrollment due to presence of exclusion criteria, it is predicted 
that an average of 20% of women who meet inclusion criteria at each site will be 
consented and enrolled in this study. This 20% estimate provides an average of 88 
women enrolled at each site, totaling 1,320 women across all participating centers.   
2.6 PARTICIPANT SELECTION 
The population to be studied in this clinical trial is pregnant women >18 years of 
age at 10-14 weeks completed weeks gestation with a history of spontaneous preterm 
birth at >20 to <37 completed weeks gestation in a previous singleton pregnancy. 
Spontaneous preterm birth will be defined in accordance with the American College of 
Obstetricians and Gynecologists as premature birth following spontaneous preterm 
labor, preterm spontaneous rupture of membranes, or cervical insufficiency, and will 
 37 
not include indicated or iatrogenically induced preterm delivery for maternal or fetal 
conditions.48 Women with previous preterm birth during a singleton gestation are at a 
2.5-5.6 fold increased risk of recurrent premature delivery in a subsequent singleton 
gestation, which necessitates the development of novel gestation prolonging 
interventions for this cohort.49,50 Observational studies and theoretical reviews suggest 
that genetically modulated immunologic hyper or hypo-responsiveness to vaginal non-
commensals predisposes a subset of women to spontaneous preterm labor.51-54 It is 
possible that women predisposed to recurrent spontaneous preterm birth in singleton 
gestations are those subject to a gene-environment interaction that favors a 
maladaptive immune response.53 By enrolling women with previous spontaneous 
preterm birth in singleton gestations, the proposed study aims to target a cohort of 
women specifically prone to microbe induced premature labor. 
In addition to biologic and public-health implications, enrollment of women with 
prior spontaneous preterm births fulfills practical requirements. The increased risk of 
prematurity in this group also allows for a more realistic sample size and provides a 
cohort of women with high motivation for study adherence and completion. A recent 
randomized, double blind, placebo-controlled trial attempted to investigate the efficacy 
of daily probiotic therapy in preventing preterm birth among pregnant women with 
asymptomatic BV.43 This study primarily recruited women without a history of prior 
preterm birth from public clinics in Rio de Janeiro, Brazil. Due to the low incidence of 
preterm birth in the study population (<2.5%) and high rate of participant attrition (38%) 
the study was underpowered and statistically significant effects could not be concluded. 
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By only recruiting women at high risk for spontaneous preterm birth the proposed study 
intends to avoid the statistical shortcomings of the above clinical trial. 
A gestational age of 10-14 completed weeks at time of enrollment will be an 
additional inclusionary criteria due to previously described evidence (sect. 2.2a-c) that 
indicates an increased risk for spontaneous preterm birth when abnormal vaginal flora 
or insufficient vaginal lactobacilli is detected in the late first and early second 
trimester.16,17,20-22 This gestational age will also allow for determination of singleton 
gestation and may confer benefit in mitigating the increased risk of mid-trimester 
miscarriage associated with BV and AV. In accordance with standards released by the 
American College of Obstetricians and Gynecologists, gestational age will be determined 
prior to enrollment and randomization by last menstrual period consistent with 
ultrasound, or if last menstrual period unknown consistent with ultrasound alone.55  
Exclusion criteria will be minimal to improve the generalizability of the trial. 
Women using vaginal progesterone prior to or at the time of enrollment, those being 
actively treated for a systemic or vaginal infection at enrollment, and women with a 
multifetal gestation or with a detected major fetal abnormality will be excluded.  
2.7 INTERVENTION 
 The intervention in the proposed trial will be a fast release intravaginal probiotic 
tablet containing at least 109 CFUs of lyophilized Lactobacillus brevis CD2, Lactobacillus 
salivarius subspecies salicinius FV2, and Lactobacillus plantarum FV9 applied daily from 
the from the time of enrollment until delivery. The intravaginal route was chosen due to 
the need to quickly establish or enrich a lactobacilli dominant vaginal microbiome. As 
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previously described (sect. 2.2a-b), trials investigating intravaginal probiotics show 
establishment of a vaginal microbiota rich in lactobacilli within 5-7 days.32-37 Since 
asymptomatic abnormalities of the vaginal flora early in gestation are associated with 
preterm delivery, quick normalization of existent abnormalities and early prevention of 
dysbiosis will be key for optimization of probiotic supplementation.  
The dose of 109 viable organisms per tablet was chosen due to the precedent set 
by previous studies of the same probiotic formulation (sect. 2.3a.) and previous research 
regarding the dose of lactobacilli necessary to effectively colonize vaginal flora.34,35 In 
2001, Reid et al. investigated the rate of conversion to normal vaginal flora among 
women with BV who were randomly assigned to different doses of a oral lactobacilli 
probiotic.56 The only women who exhibited significant conversion to normal vaginal 
flora after 28 days of treatment were those assigned a probiotic with >109 viable 
lactobacilli per capsule.  
Probiotics will be dosed daily from the time of enrollment until delivery to confer 
optimal therapeutic benefits. In their study of intravaginal L. brevis CD2, L. salivarius 
salicinius FV2, and L. plantarum FV9, Mastromarino et al. recruited women with BV and 
a history of recurrent BV (sect. 2.3a.).34  A 100% conversion to normal or intermediate 
flora was observed among women receiving probiotic immediately after completion of 
their 8-day course, but 40% of these women were BV positive again 2 weeks later.7,34 
Other studies noted much lower rates of relapse at 2-4 weeks after completion of 
probiotic treatment, but these investigations did not specifically enroll women with a 
history of recurrent BV.37,38,40 Since the optimal duration of probiotic therapy to confer 
 40 
lasting protection against abnormal flora appears variable across women with different 
predispositions towards dysbiosis, daily therapy will span the length of gestation. 
The formulation of probiotic was selected due to its success in treating abnormal 
vaginal flora and maintaining normal vaginal flora, as displayed in the methodologically 
sound investigations composed by Hemalatha and Mastromarino et al. (sect.  2.3a).34,35 
The intravaginal probiotic tablet containing 109 L. brevis CD2, L. salivarius salicinius FV2, 
and L. plantarum FV9 is available under the trade name “Florisia” and produced by VSL 
Pharmaceuticals, Inc. (USA). The tablets include starch, lactose, ascorbic acid, sodium 
bicarbonate, adipic acid, stearic acid, and magnesium stearate, which are excipients that 
facilitate fast release of lactobacilli to the vaginal environment and enhance vaginal cell 
adhesion and metabolic activity of lactobacilli.57 These tablets maintain a viability of 
>109 CFUs of lactobacilli organisms for 12 months when stored at 4°C (39.2°F).57 This 
formulation, including excipients, was developed by Maggi and associates in their 
evaluation of different species of Lactobacillus for inclusion in vaginal probiotic tablets.57  
In testing the properties of various strains of lactobacilli for formulation into 
probiotic tablets, Maggi et al. determined that L. brevis CD2 and L. plantarum FV9 were 
highly adherent to epithelial cells in comparison to other strains of lactobacilli.57 After 
performing adherence assays, 90% of HeLa cells inoculated with 109 L. brevis CD2 or 109 
L. plantarum FV9 were colonized with a mean of 25 lactobacilli per cell, while other 
species of Lactobacillus showed a cell colonization rates as low as 19%. In a follow-up 
study Mastromarino et al. also found a high adherence rate of L. brevis CD2 to HeLa cells 
following adherence assay.58 Mastromarino et al. study proceeded to report high 
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inhibitory activity of L. salivarius salicinius FV2 against the growth of Gardnerella 
vaginalis, as demonstrated through disc diffusion assays, and efficient coaggregation of 
L. salivarius salicinius FV2 with Gardnerella vaginalis and Candida albicans on tissue 
culture trays. The results of Maggi and Mastromarino et al. suggest that a probiotic 
containing L. brevis CD2, L. salivarius salicinius FV2, and L. plantarum FV9 can 
competitively exclude potentially harmful organisms from vaginal mucosa through 
effective epithelial cell adhesion, produce antimicrobial compounds capable of 
inhibiting pathogen growth, and infiltrate biofilms and isolate pathogenic or 
opportunistic organisms through coaggregation on vaginal mucosa. Additionally, this 
probiotic formulation might exert an anti-inflammatory effect by conferring a reduction 
in the pro-inflammatory cytokines interleukin-1, beta and interleukin-6 (sect. 2.3a.).35  
Finally, probiotics are an acceptable intervention for this population of pregnant 
women due to documented safety during gestation and low risk of mild side effects. An 
integrative review by VandeVusse et al. evaluated randomized clinical trials, quasi-
experiments, prospective cohort studies, and observational investigations of prenatal 
oral and intravaginal probiotic supplementation published between 1990 and 2011.30 In 
the assessment of maternal and neonatal outcomes in 37 included publications, 
investigators failed to identify significant risk to mother, fetus, or infant associated with 
Lactobacillus or Bifidobacterium supplementation during gestation. On the contrary, this 
review noted reduction in incidence of BV, increased vaginal lactobacilli colonization, 
and reduction in gestational diabetes and preeclampsia with probiotic use during 
pregnancy. Findings of this integrative review are supported by a meta-analysis of 
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randomized clinical trials and another systematic review, which both evidenced the 
safety of prenatal lactobacilli probiotics.31,59 In studies that specifically evaluated 
intravaginal L. brevis CD2, L. salivarius salicinius FV2, and L. plantarum FV9, none of the 
women assigned to probiotic reported adverse events or side effects associated with 
therapy.34,35 Studies of other intravaginal probiotic formulations, including those 
requiring long-term therapy, also fail to report significant side effects or adverse events 
requiring discontinuation of study participation.60-62 Since previous research documents 
the safety/acceptability of lactobacilli probiotics and the estimated risk of developing 
bacteremia from lactobacilli probiotics is less than 1 in 1 million users, this therapy is a 
safe and promising approach for modulation the vaginal environment.63 
2.8 OUTCOME VARIABLES  
The primary outcome in the proposed study will be the frequency of 
spontaneous preterm birth at >20 and <37 completed weeks gestation. These upper and 
lower limits of prematurity are in accordance with the classification of preterm birth 
established by the World Health Organization and US Centers for Disease Control and 
Prevention and follow the precedent set by multiple seminal articles in preterm birth 
research.45,47,64 Use of a common primary outcome in prematurity research will allow 
straightforward comparison between the results of this and other trials.47,65 The primary 
outcome will be stratified for maternal race/ethnicity, cervical cerclage or 17 alpha-
hydroxyprogesterone caproate (17P) supplementation during gestation, and level of 
intervention compliance as these factors have the potential to alter the risk of 
spontaneous prematurity.45,47,66  
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Following the precedent set by Meis et al. in their seminal publication on the use 
of 17P to prevent recurrent spontaneous preterm birth, secondary outcomes will 
further assess outcomes of pregnancy and incidence of maternal and fetal and neonatal 
events associated with prematurity. Gestational age at delivery will be specifically 
quantified and compared between groups to assess for trends in extent of prematurity. 
Incidence of maternal and infant complications of prematurity will be compared 
between groups to determine any difference in the short-term morbidities of preterm 
birth. The pregnancy outcomes and neonatal/maternal complications to be assessed will 
be constructed based on the most common morbidities of prematurity, precedents set 
by other clinical investigations, and in accordance with guidelines for preterm birth 
clinical trials published in the Journal of Reproductive Sciences.47,65-68  
Two interim analyses will be performed in collaboration with the Data and Safety 
Monitoring Board when outcome data is available for one-third and two-thirds of the 
sample size. Interim analyses will determine if the study should be continued, modified, 
or stopped early due to significant benefit or harm. The group sequential method 
described by Lan and DeMets and the O’Brian-Fleming boundary will be utilized to 
preserve the study alpha and reduce the risk of inappropriate early-stopping.69,70  
2.9 SAMPLE SIZE RATIONALE 
A sample size of 1,065 was calculated to detect an 18% reduction in the rate of 
spontaneous preterm birth at >20 to <37 weeks completed gestation among women 
receiving probiotic therapy. A total of 1,172 women will be enrolled to account for a 
10% attrition rate. Attrition rate of 10% was estimated based on the 9.5% attrition rate 
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observed in a study of daily intravaginal progesterone supplementation from 24-34 
weeks gestation among women at high risk for spontaneous preterm birth.71 This 
sample size was calculated for a two-tailed test with an alpha of 0.05 and beta of 0.2. 
The 30% level of outcome was determined through examination of the National 
Institute of Child Health and Human Development Consecutive Pregnancies Study, 
which rigorously collected data on the outcome of consecutive pregnancies among 
51,086 women living in Utah between 2002 and 2010.50 After controlling for age, race, 
body mass index, insurance status, smoking, alcohol, illicit drug use, and chronic medical 
conditions, investigators found that 30% of women with a preterm birth in their first 
delivery experienced a subsequent preterm birth in their second delivery.  
Expected effect size was determined based on the findings of Myhre et al. in 
their previously detailed case-controlled study (sect. 2.3b). Myhre and colleagues 
detected a statistically significant 18% decrease in odds (AOR: 0.820; 95% CI: 0.681-
0.986; p=0.035) of spontaneous preterm birth among women who reported a high 
(2.85x109-2.0x1011 CFUs) oral intake of probiotic organisms per day during the first 4-5 
months of gestation. Though this intervention utilized a different probiotic formulation 
delivered orally, the proposed mechanism of probiotic action (normalization of vaginal 
flora, inhibition of pathogen/opportunist proliferation, reduction in local inflammation) 
is the same for strains of effective oral and intravaginal probiotics. Since there are no 
previous studies of intravaginal probiotic therapy throughout gestation that report a 
pregnancy outcome between probiotic and placebo groups, an 18% effect size is the 
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CHAPTER 3: STUDY METHODS 
3.1 STUDY DESIGN:  
The proposed study is a randomized, double blind, placebo-controlled, 
multicenter clinical trial.  
3.2 SAMPLING AND STUDY POPULATION:  
Participants will be consecutively sampled from the population seeking care at 15 
participating academic health centers and affiliated offices. The target population is 
women >18 years of age at 10-14 completed weeks gestation with spontaneous preterm 
birth at >20 and <37 completed weeks gestation in their previous singleton pregnancy. 
Previous spontaneous preterm birth is defined as birth following spontaneous preterm 
labor, preterm spontaneous rupture of membranes, or cervical insufficiency. Previous 
spontaneous preterm birth will be confirmed by medical chart review. Gestational age 
will be determined by last menstrual period (LMP) consistent with ultrasound prior to 
enrollment and randomization, or if LMP unknown consistent with ultrasound alone.   
Women using vaginal progesterone prior to or at the enrollment, those being 
actively treated with an antibiotic, and women with a multifetal gestation or with a 
known major fetal abnormality will be excluded. If a major structural anomaly is 
detected later in gestation these women will be excluded. Non-English or non-Spanish 
speaking women and those planning to deliver elsewhere will be excluded. 
3.3 SUBJECT PROTECTION AND CONFIDENTIALITY: 
An application to involve human subjects in research will be submitted to the Yale 
Human Investigation Committee (HIC) and Yale Institutional Review Board (IRB) for 
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approval. All study personnel will complete mandatory human subjects protection 
training and Health Insurance Portability and Accountability Act (HIPAA) privacy training. 
Proof of training will be included in the original HIC application. Once Yale IRB approval is 
attained participating sites will obtain IRB approval through their academic centers. 
Documentation of IRB approval and proof of personnel training will be will be kept on file 
at each participating site and sent to the Yale coordinating center prior to site approval.  
Informed consent will be obtained from potential participants prior to study 
enrollment by qualified personnel using an English or Spanish IRB approved consent. The 
consent process will include description of study procedures, potential benefits, risks, 
and inconveniences, confidentiality, and right to withdraw. Consents will be kept in a 
locked cabinet at each site and only approved personnel will have keys. Participants will 
be assigned a study ID upon enrollment and the link between participant name and ID 
will be saved on a password protected, electronic document on an encrypted computer 
at each site. Study data from the participating sites that is visible to the YDSCC will be 
coded by study ID, without reference to name or maternal birth date. Electronic medical 
records will only be accessed on academic center approved, encrypted devices. Any 
paper copies of participant medical records or Case Report Forms (CRFs) will be stored in 
locked cabinets. Vaginal swabs will be de-identified with study ID and stored in an -80°F 
locked freezer in a locked research facility. 
3.4 RECRUITMENT: 
 Potential participants will be recruited from each academic center and their 
affiliated offices. Potential participants will be identified by research staff upon routine 
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visits to the obstetric or maternal-fetal-medicine department at each center. Research 
staff will present the study to potentially eligible women. If interested, women will sign 
an informed consent and research staff will then screen for inclusion and exclusion 
criteria. IRB approved English and Spanish flyers (App.XI) will be distributed to offices 
whose practitioners deliver at participating centers. If a potential participant contacts 
study personnel a research visit will be scheduled at the local academic site and the 
consent and screening process will proceed as above. Upon eligibility determination 
participants will be enrolled and randomized to probiotic or placebo by the YDSCC.  
3.5 STUDY VARIABLES AND MEASURES:  
 3.5a Intervention: The intervention is a fast release, intravaginal probiotic tablet 
containing >109 CFUs of lyophilized Lactobacillus brevis CD2, Lactobacillus salivarius 
salicinius FV2, and Lactobacillus plantarum FV9, which will be applied daily from the time 
of enrollment until delivery. Tablet excipients are starch, lactose, ascorbic acid, sodium 
bicarbonate, adipic acid, stearic acid, and magnesium stearate. The placebo tablet will be 
dosed identically and contain all excipients. Tablets will be received by the YDSCC in 
small batches from VSL Pharmaceuticals, Inc. and stored at 39-40°F. Each batch will be 
subject to a random quality check by VSL Pharmaceuticals prior to shipment to ensure 
against contamination. Tablet packets will be dispensed to women by the site research 
assistant 3-7 days after study enrollment in packets containing 280 tablets (40 weeks of 
tablets). Undistributed probiotic tablets will be discarded after 2.5 months as tablet 
viability is only guaranteed for 12 months. Each woman will be taught how to apply the 
tablet at the enrollment visit and instructed to refrigerate the tablet at 39-40°F. Follow-
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up visits to monitor intervention compliance, side effects or adverse events, and to 
collect vaginal swabs will occur every 8 weeks after enrollment until delivery. Women 
will receive a reminder phone call and text message 3 days prior to their follow-up. 
3.5b Primary Outcome: The primary outcome will be the proportion of women 
who experience spontaneous preterm birth at >20 and <37 completed weeks gestation. 
Spontaneous preterm birth will be defined as birth following spontaneous preterm labor, 
preterm spontaneous rupture of membranes, or cervical insufficiency (App.I, Table 4).  
3.5c Secondary Outcomes: Secondary outcome measures will compare the 
specific timing of delivery and incidence of neonatal and maternal outcomes associated 
with prematurity and/or infection between the study groups. Specific gestational week 
at spontaneous delivery will be compared between probiotic and placebo participants 
and a Kaplan-Meier curve will be constructed to depict the group trends in gestational 
length (App.I, Table 4). The following fetal and neonatal outcomes will be compared 
between groups: fetal death, neonatal intensive care unit admission, birth weight, Apgar 
score, supplemental oxygen use, ventilatory support, transient tachypnea, respiratory 
distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, 
periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity, 
sepsis, or neonatal death (App.I, Table 5). The following maternal outcomes will be 
compared between groups: preterm premature rupture of the membranes, tocolytic 
therapy for preterm labor, antepartum corticosteroid administration, mode of delivery, 
clinical chorioamnionitis, postnatal sepsis, postnatal endometritis, vaginal infection or 
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antibiotic use during gestation, gestational diabetes, preeclampsia/eclampsia, placental 
abruption, and recurrent antepartum hemorrhage (App.I, Table 6). 
3.5d Baseline Variables: The baseline variables will include: gestational age at 
randomization, gestational length of previous preterm delivery, number of previous 
preterm deliveries, parity, age, race/ethnicity, body mass index before pregnancy, 
prevalence of systolic heart failure, renal failure, hypertension requiring medication and 
diabetes mellitus type 2, level of education, pregnancy and pre-pregnancy substance use, 
combined household income, Medicaid eligibility, Women, Infants, and Children (WIC) 
eligibility, marital status, and level of physical activity (App.I, Table 3).  
3.6 METHODOLOGICAL CONSIDERATIONS: 
 3.6a Assignment of Intervention, Blinding of Intervention, Blinding of Outcome: 
Participants will be assigned to probiotic or placebo by simple random allocation. A 
research assistant at the YDSCC, who is otherwise unaffiliated with the trial, will use an 
electronic sequence generator to randomly generate a 1 or 2, which will be accordingly 
printed on paper and sequentially placed in 1,172 opaque envelopes. A 1 will correspond 
to probiotic allocation and 2 to placebo. Envelopes will be sequentially stored in a locked 
cabinet at the YDSCC. When a participant is enrolled at each site the YDSCC will be 
informed by a site research assistant and the unaffiliated YDSCC assistant will collect the 
next available envelope. The assistant will open the envelope and link the study 
participant site ID with the study allocation and record the participant enrollment 
number (App.I, Table 1). According to allocation the YDSCC assistant will code a probiotic 
or placebo packet, which are identical in appearance, with the participant site ID and 
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ship the packet to the appropriate study site. The YDSCC assistants will be the only 
individuals with access to the spreadsheet that links study ID to allocation. Probiotic and 
placebo will be identical in appearance. The Principal Investigator (PI), research members 
at each site, and participants’ medical care provider(s) will not be informed of allocation. 
3.6b Compliance: Compliance with the intervention will be monitored at each 
follow-up. The probiotic/placebo packet that participants receive after enrollment will 
contain an IRB approved form to record daily suppository application (App.IX). This form 
will be brought to each follow-up visit and compliance will be documented. 
3.6c Monitoring of Adverse Events: Adverse events are not anticipated in this 
study, however rigorous monitoring will be performed. An independent, non-blinded 
Data and Safety Monitoring Board (DSMB) will be established at Yale in accordance with 
the Yale HIC guidelines. The DSMB will review side effect and adverse event tracking logs 
(App.VI) and data from any participant hospitalizations at 8-week intervals. If significant 
adverse events attributed to probiotic or placebo are discovered the study will be halted, 
all involved personnel will be unblinded, and medical care providers will be informed. 
3.6d Data Collection: Research personnel at each site will use paper CRFs to 
collect participant information at each study visit (App.I: Table 2; App.V-VI). Personnel 
will transfer information from CRFs to a password protected RedCAPTM database that is 
only accessible on academic center encrypted devices. Each participant will be given 
their own file within the database that contains electronic versions of each CRF. Site ID 
will be used in place of name and date of birth as identifiers in the database. Research 
personnel at each site will only have access to files from participants enrolled at their 
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site. Research personnel at the YDSCC will have access to de-identified participant files 
from each participating site. The use of a centralized database will allow for quick 
communication between participating sites and the YDSCC, simplifying data tracking and 
eventual data analysis. All paper (source) CRFs will be stored with the consents. 
Pregnancy outcome data will be collected directly from the patients’ medical 
record by a trained research nurse/assistant at each site and transcribed into the 
RedCAPTM database (App.VII). Pregnancy outcome data will be finalized and confirmed in 
RedCAPTM no later than 30 days after delivery for each participant. All data will be stored 
in RedCAPTM and/or in the locked cabinets for at least for at least 3 years after study the 
conclusion. Vaginal swabs from the posterior fornix and lateral vaginal wall will be 
collected from all women at enrollment and 8, 12, and 24-week follow-ups. Specimens 
will be stored at each participating academic center at -80°F for future analysis and a 
specimen collection form will be completed (App.VIII). 
3.6e Sample Size Calculation: A total of 1,172 women, 586 women in each study 
arm, will be enrolled to detect an 18% reduction in the expected 30% incidence of 
spontaneous preterm birth in the study population. Sample size was calculated for a 
two-tailed test, alpha of 0.05, beta of 0.2, and accounting for a 10% attrition rate.  
3.6f Analysis: Baseline characteristics will be compared between groups with chi-
square or Fisher’s exact test for categorical values, Mann-Whitney-U test for non-
parametric continuous variables, and student’s t-test for parametric continuous variables 
The primary outcome will be assessed according to the intention-to treat (ITT) 
principle. The ITT population will be women for whom gestational age at delivery is 
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known. The proportion of women experiencing preterm birth at >20 and <37 completed 
weeks gestation will be compared between probiotic and placebo group with the chi-
squared test for univariate analysis (App.I, Table 4). The primary outcome will be 
stratified by maternal race/ethnicity, gestational treatment with 17P or cervical cerclage, 
and level of intravaginal tablet compliance. In collaboration with the DSMB, interim 
analyses will occur when outcome data are available for one-third and two-thirds of the 
study sample size. Interim analysis will be performed in accordance with the Lan-DeMets 
group sequential methods and the O-Brian-Fleming boundary.   
Secondary analyses will include an evaluation of the duration of pregnancy in the 
probiotic and placebo groups. The Kaplan-Meier method and log-rank test will be used to 
assess time to delivery between groups with adjustment for gestational age at entry into 
the study. The chi-squared test will be used to compare the proportion of women with 
spontaneous preterm birth at <39, <35, <32, <28, and <20 completed weeks gestation. 
The chi-squared test, student’s t-test for parametric continuous variables, and the Mann-
Whitney-U test for non-parametric continuous variables will be used to compare 
neonatal and maternal outcomes of pregnancy between the probiotic and placebo 
groups (App.I, Table 5-6). A p<0.05 will be considered significant.  
3.6g Timeline and Resources: The study will last 2 years and the recruitment 
phase will last 14.5 months. Data collection and entry will occur on a rolling basis. Study 
start-up will last approximately 1 year and include identification of a PI at each site, 
designation and training of research staff, IRB approval, establishment of the YDSCC, 
construction of the RedCAPTM database, coordination with VSL pharmaceuticals, 
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attainment of shipping supplies, location of a 39-40°F refrigerator at the YDSCC, and 
attainment of space in a locked -80°F refrigerator and one clinic room at each site.  
At minimum the research team at each site will be composed of a PI, qualified 
personnel for sonographic gestational age determination and vaginal swab collection, 
and at least one research nurse/research assistant to screen for study eligibility and 
accurately gather information from the medical record. The YDSCC will consist of 
otherwise unaffiliated research staff member(s) to handle study allocation and shipment 
of study packets, a data specialist to manage the RedCAPTM database, and at least one 
statistician. The DSMB will comprise qualified personnel at the Yale Medical Center.  
A large proportion of cost and resources associated with this investigation will be 
related to staffing needs. The other main cost will be tablet packets obtained from VSL 
pharmaceuticals. At least 586 packets containing 280 probiotic tablets and 586 packets 
containing 280 placebo tablets, totaling 164,080 probiotic and placebo tablets, will be 
required for this study. The cost of intravaginal probiotic tablets ranges from $0.80-
$3.00+ per tablet. Other study resources include 9,376 Dacron Swabs for vaginal flora 
sample collection and ultrasound gel for 1,172 sonograms. Mobile ultrasound machines 
owned by the academic centers will be used for gestational age sonograms. The 
RedCAPTM database is a free platform offered through Vanderbilt University and no cost 
will be associated with its use.
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CHAPTER 4: CONCLUSION 
4.1 ADVANTAGES AND DISADVANTAGES 
 Several strengths are associated with the proposed investigation. First, the 
proposed study is a randomized, double blind, placebo-controlled clinical trial. This 
design decreases risk of confounding and bias thereby increasing confidence in the 
verity of the study results. The study will also be generalizable to a wide population of 
women across the nation due to the multicenter structure, inclusion of Spanish speaking 
women, and short list of exclusion criteria. Though the study findings will not be directly 
generalizable to women without a history of spontaneous preterm birth, it is reasonable 
to expect benefit with this intervention among women without preterm history.1 The 
selection of women at high risk for spontaneous preterm birth is an advantage as these 
women stand to benefit the most and will be more motivated towards study adherence 
and participation. Finally, the study design and large sample size in this investigation of 
probiotics for the prevention of spontaneous preterm birth fills a gap in the literature 
noted by multiple systematic reviews and a Cochrane meta-analysis.2-4  
 Some of the strengths of the proposed study also pose limitations. The large 
sample size and use of a multicenter design will require a significant start-up time for 
training and site recruitment. Since the study will be completed within two years, a 
significant number of personnel will be necessary to recruit participants, complete study 
follow-up visits, and collect study data across the participating sites. This study is also 
limited by the lack of thorough understanding of the mechanism of action of different 
species of Lactobacillus  within the vaginal microbiome. The selected probiotic 
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formulation shows benefit in eliminating and preventing the colonization of the vaginal 
flora with opportunistic and pathogenic organisms.5-8 However, lack of side-by-side trials 
of different probiotic formulations for the promotion of vaginal health makes it difficult 
to predict the best choice of formulation. It is possible that different species are better 
capable of enriching the vaginal microbiome. Finally, the intravaginal route of probiotic 
administration may be unfavorable to some women and deter against participation.  
4.2 CLINICAL AND PUBLIC HEALTH SIGNIFICANCE 
 Preterm birth is the national leading cause of neonatal morbidity and mortality.9 
Nearly 500,000 infants are born prematurely each year in the United States and the 
national yearly cost of prematurity averages over 26 billion dollars.10 Since 25-50% of 
spontaneous preterm births are attributed to infection and inflammation despite 
current screening and treatment guidelines, the introduction of a therapy capable of 
further reducing the incidence microbe induced preterm delivery would be extremely 
meaningful.11,12 The proposed probiotic intervention is a relatively low cost, low risk 
therapy that could be easily added to the standard prenatal vitamin regimen prescribed 
during gestation. If probiotic therapy decreases the incidence of spontaneous preterm 
birth by 18% in this trial then 32 enrolled women will be spared preterm delivery and its 
consequences. If this level of effectiveness is generalizable to women of all gestational 
histories, the addition of probiotics to the prenatal regimen could result in a decrease in 
the preterm birth rate by almost 60,000 births per year. Probiotic therapy is a promising 
novel intervention for the prevention of spontaneous preterm birth and deserves 
thorough investigation.  
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APPENDIX I: TABLES  
 
Table 1: Random Allocation Spreadsheet 
Participant ID a001 a002 b001 b002 c001 c002 d001 d002 e001 e002   
Allocation             1 2 2 1 1 2 1 1 2 2 
  
Enrollment #  1 2 3 4 5 6 7 8 9 10 11 12 
 
























T0 Enrollment X X X  X    
T1 3-7 days    x     
T2 8 weeks     X X X  
T3 16 weeks     X X X  
T4 24 weeks     X X X  
T5 32 weeks      X X  
T6 40 weeks      X X  
Birth** N/A      X X X 
*Study visits will terminate at the time of delivery   **The birth study visit will not include an in-person encounter, a phone call will 

































Gestational age at randomization Mean weeks + SD Mean weeks + SD 
Gestational age at most recent sPTD Mean weeks + SD Mean weeks + SD 
Number of previous sPTD Median, + IQR Median, + IQR 
      1 previous sPTD Number, % Number, % 
      >1 previous sPTD Number, % Number, % 
Parity Median, + IQR Median, + IQR 
Age at enrollment Mean years, + SD Mean years, + SD 
Race / Ethnicity   
      Non-Hispanic black Number, % Number, % 
      Non-Hispanic white Number, % Number, % 
      Hispanic Number, % Number, % 
      Asian Number, % Number, % 
      Other Number, % Number, % 
BMI before pregnancy Mean, + SD Mean, + SD 
Education level Median years, + IQR Median years, + IQR 
Pre-existing medical conditions   
      Systolic heart failure with EF <40 Number, % Number, % 
      Renal failure with CrCl <30 Number, % Number, % 
      Hypertension requiring medication Number, % Number, % 
      Diabetes Mellitus type 2 Number, % Number, % 
      Antiphospholipid Syndrome Number, % Number, % 
Substance use   
      Smoking before pregnancy Number, % Number, % 
      Smoking during pregnancy Number, % Number, % 
      Alcohol use during pregnancy Number, % Number, % 
      Illicit drug use during pregnancy Number, % Number, % 
Socioeconomic status   
      Combined household income Mean, + SD Mean, + SD 
      At or below poverty level Number, % Number, % 
      Medicaid eligible Number, % Number, % 
      Receiving WIC Number, % Number, % 
Marital status   
      Married or living with partner Number, % Number, % 
      Never married Number, % Number, % 
      Divorced, separated, or widowed  Number, % Number, % 
Physical activity   
      No exercise Number, % Number, % 
      Light exercise (>1x/week) Number, % Number, % 
      Moderate exercise (1-2x/week) Number, % Number, % 
      Frequent exercise (>3x/week) Number, % Number, % 
† - Denotes statistically significant difference (p<0.05)  
sPTD: spontaneous preterm delivery, BMI: Body mass index - calculated as (weight kilograms / height meters2) 




















Relative Risk  
(95% CI) 
Spontaneous preterm delivery at  
>20 & <37 completed weeks 
Number, % Number, %  
      Non-Hispanic black Number, % Number, %  
      Non-Hispanic white Number, % Number, %  
      Hispanic Number, % Number, %  
      Received 17 alpha-
hydroxyprogesterone caproate 
Number, % Number, %  
      Underwent cervical cerclage Number, % Number, %  
      High intervention compliance  
      (average >5 days/week) 
Number, % Number, %  
      Moderate intervention compliance 
      (average >3 to <5 days/week) 
Number, % Number, %  
      Low intervention compliance 
      ( average <3days/week) 
Number, % Number, %  
Spontaneous delivery at:     
      >20 & <39 completed weeks Number, % Number, %  
      >20 & <35 completed weeks Number, % Number, %  
      >20 & <32 completed weeks Number, % Number, %  
      >20 & <28 completed weeks Number, % Number, %  
      <20 completed weeks Number, % Number, %  
Indicated preterm delivery for 
maternal/fetal complication 
Number, % Number, %  
Term delivery at:    
      >37 & <39 completed weeks Number, % Number, %  
      >39 & <41 completed weeks Number, % Number, %  
Mean gestational age, all deliveries Mean week, + SD Mean week, + SD  
CI: Confidence interval  








Fetal death: antepartum or intrapartum Number, % Number, %  
NICU admission  Number, % Number, %  
Birth weight  Mean grams, + SD Mean grams, + SD  
      <2500 grams Number, % Number, %  
      <1500 grams Number, % Number, %  
Apgar Score     
          1 minute Mean, + SD Mean, + SD  
          5 minute Mean, + SD Mean, + SD  
Supplemental Oxygen  Number, % Number, %  
Ventilatory support  Number, % Number, %  
Transient tachypnea  Number, % Number, %  
Respiratory distress syndrome Number, % Number, %  
Bronchopulmonary dysplasia  Number, % Number, %  
Intraventricular Hemorrhage (any grade) Number, % Number, %  
      Grade 1 Number, % Number, %  
      Grade 2 Number, % Number, %  
      Grade 3 Number, % Number, %  
      Grade 4 Number, % Number, %  
Periventricular leukomalacia Number, % Number, %  
Necrotizing enterocolitis  Number, % Number, %  
Retinopathy of prematurity Number, % Number, %  
Sepsis Number, % Number, %  
Neonatal death (<28 days)  Number, % Number, %  
NICU: Neonatal intensive care unit; CI: Confidence interval 
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Preterm premature rupture of the 
membranes (pPROM)  
Number, % Number, % 
 
Admission for preterm labor Number, % Number, %  
Tocolytic therapy for preterm labor  Number, % Number, %  
Antepartum corticosteroid 
administration for fetal lung maturity 
Number, % Number, % 
 
Mode of delivery     
      Vaginal Number, % Number, %  
      Cesarean section Number, % Number, %  
Diagnosed vaginal infection during 
gestation (total) 
Number, % Number, % 
 
      Bacterial vaginosis Number, % Number, %  
      Aerobic vaginitis Number, % Number, %  
      Vulvovaginal candidiasis Number, % Number, %  
      Other Number, % Number, %  
Antibiotic use during gestation  Number, % Number, %  
      Antibiotic use for vaginal infection Number, % Number, %  
Complications of Pregnancy Number, % Number, %  
      Clinical chorioamnionitis  Number, % Number, %  
      Gestational diabetes Number, % Number, %  
      Preeclampsia or eclampsia Number, % Number, %  
      Placental abruption Number, % Number, %  
      Recurrent antepartum hemorrhage   Number, % Number, %  
Complications after delivery    
      Postnatal endometritis Number, % Number, %  
      Postnatal sepsis Number, % Number, %  








APPENDIX II: RESEARCH PARTICIPANT CONSENT FORM  
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Probiotic therapy for the prevention of recurrent spontaneous preterm birth 
Principal Investigator: Kali O’Dell PA-S2 
Funding Source: To be determined 
 
 
INVITATION TO PARTICIPATE AND DESCRIPTION OF PROJECT 
You are invited to participate in a research study looking at whether probiotics are 
able to reduce the number of women who have repeated preterm birth. You are being 
asked to take part in this study because you had a preterm birth in the past that was not 
planned. Preterm births that are not planned can happen for many reasons. One reason 
is infection and inflammation that might not cause symptoms. We think that probiotics 
might reduce infection and inflammation and that women who take probiotics when they 
are pregnant may have a lower risk of preterm birth. Probiotics are defined by the World 
Health Organization as “live microorganisms, which when administered in adequate 
amounts, confer a health benefit on the host.” The probiotic tablets we are using contain 
Lactobacillus bacteria, which are the same kind of bacteria (also called “flora”) that are 
normally present in your vagina and may help protect you against abnormal bacteria. 
About 1,000 women will take part in this study at 15 medical centers across the country. 
  In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed judgment.  This 
consent form gives you detailed information about the research study, which a member 
of the research team will discuss with you.  This discussion should go over all aspects of 
this research: its purpose, the procedures that will be performed, any risks of the 
procedures and possible benefits. Once you understand the study, you will be asked if 
you wish to participate; if so, you will be asked to sign this form. 
 
DESCRIPTION OF PROCEDURES 
If you agree to be in the study, the following will happen to you: 
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1- We will record some information about this pregnancy and past pregnancies and 
information about your health and personal history. 
2- You will have an ultrasound to figure out the age of your baby and see if you are 
having one baby or multiple babies.  
3- The research we are asking you to take part in involves placing a probiotic tablet or 
placebo tablet into your vagina one time a day, in a similar way that you would 
insert a tampon. The placebo tablet does not contain Lactobacillus bacteria, just 
the ingredients that help the pill stay together and dissolve in your vagina. You 
would do this every day until you go into labor and deliver your baby. You would 
keep track of every time you place a probiotic tablet using a provided recording 
sheet. This will help us keep track of how often you remember to place the tablet. 
4- Some women will be randomly chosen to receive probiotic tablets and some will 
be randomly chosen to receive placebo tablets. We have no way of telling which 
group you will be assigned to, a computer program will randomly pick numbers to 
determine which group you will be in. 
5- The research we are asking you to take part in also involves follow-up visits. You 
will return to the medical center for follow-up visits one time every 8 weeks. We 
will call or text you 3 days ahead of your visit to remind you of your appointment 
and remind you to bring the recording sheet you’ve been filling out. We will also 
call you one time after you give birth to see how often you used the probiotic 
tablets in the days/weeks between your last follow-up visit and giving birth. 
6- After delivery we will look in your medical chart and your baby’s medical chart and 
record information about the delivery and if you or your baby had an illness or 
medical problem before delivery or within 28 days after delivery. Please initial the 
statement below if you will allow this chart review: 
______ I give my permission to allow the investigators to review my baby’s medical chart 
for the above information. 
Collection of samples: 
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7- We would also like to collect samples of the bacteria in your vagina when you are 
enrolled in the study and at your first 3 follow-up visits. You are invited to allow 
these samples (called specimens) and related information to be stored (banked) 
for future research to see what kind of bacteria are in the vagina of different 
pregnant women. This may help researchers in the future learn more about how 
to prevent, find or treat abnormal bacteria.  
8- When your specimens and information are stored, we are careful to try to protect 
your identity from discovery by others. Your samples and information will receive 
a unique code. Other researchers will only receive coded samples and information, 
and will not be able to link the code to you. Strict security safeguards are in place 
to reduce the chance of misuse or unplanned release of information. Using your 
specimens for research will probably not help you. We do hope the research results 
will help people in the future. Your specimens and information will only be used for 
research and will not be sold. There is a possibility that this research may lead to 
development of products that will be commercialized. If this happens, there is no 
plan to share any financial gain with you. Research results will not be returned to 
you or your doctor.  If research results are published, your name and other personal 
information will not be given. 
9- The choice to take part is up to you. You may choose not to let us store and use 
your samples, and your care will not be affected by this decision. If you decide that 
your samples can be kept, you may change your mind at any time. Contact the 
study staff by phone or mail to let them know you do not want your samples used 
any longer.  Your samples will either be destroyed, or made anonymous (the code 
linking them to you will be destroyed).  Please initial below: 
 
I agree to allow my samples and information to be stored and used for future research as 
described above: (initial your choice) 
 
_____YES  ______No 
RISKS AND INCONVENIENCES 
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 Other research studies have shown that probiotics are safe to use when pregnant. 
However, it is possible that you will experience some vaginal itching or discharge if you 
participate in this study. There is also a very small chance you could get an infection from 
the probiotic tablets. Less than 1 in 1 million people who take probiotics with Lactobacillus 
bacteria get an infection that might be caused by the tablets. We will make sure the 
company who makes the probiotics frequently checks the batches they make to reduce 
the risk of another type of bacteria or organism contaminating the tablets. If you get a 
serious infection while you are participating in this study we will tell your doctors you are 
participating in this study so they can take the best care of you possible. Collecting 
samples of the bacteria in your vagina may be uncomfortable. A trained clinician will use 
soft swabs to collect the samples and we will try to make you as comfortable as possible 
during the collection. Participation in this study may also involve risks that are currently 
not known. Some questions may make you uncomfortable and there is the possible risk 
of loss of confidentiality.  Every effort will be made to keep your information confidential; 
however, this cannot be guaranteed. 
BENEFITS 
 A benefit of participating in this study may be a lower risk of preterm birth in your 
pregnancy. Since babies who are born early and mothers who give birth early are at higher 
risk for health problems, you any your baby may have lower risks of health problems after 
delivery if you participate. Information that we collect from you during the study may also 
give us a better understanding of why some women have preterm birth and why other 
women don’t. This could help us prevent preterm births in the future. The vaginal samples 
you give us could also help us better prevent, find, or treat abnormal vaginal bacteria in 






There is no cost to you or your insurance company for participating in this study. 
All study procedures are at no cost to you. You will be compensated for your parking and 
travel to and from the academic center for follow-up visits.  
TREATMENT ALTERNATIVES 
One alternative to this study is to not participate. Other alternatives that may 
decrease the risk of preterm birth in some women are having a cervical cerclage or taking 
17 alpha-hydroxyprogesterone caproate. Not all women are able to have these 
treatments. You can still have these treatments if you participate in this study. 
IN CASE OF INJURY 
If you are injured during the course of this study, please seek treatment and contact 
the study doctor as soon as you are able.  The Yale Medical Center does not provide funds 
for the treatment of research-related injury. You or your insurance carrier will be 
expected to pay the costs of this treatment. No additional financial compensation for 
injury or lost wages is available.  
CONFIDENTIALITY 
Any identifiable information that is obtained in connection with this study will 
remain confidential and will be disclosed only with your permission or as required by U.S. 
or State law.  Examples of information that we are legally required to disclose include 
abuse of a child or elderly person, or certain reportable diseases. The information, which 
we obtain will be identified by study number and kept in a locked file in the investigator’s 
office. When the results of the research are published or discussed in conferences, no 
information will be included that would reveal your identity unless your specific consent 
for this activity is obtained.  We will destroy the records of the research 2 years after 
publication of our results. 
Representatives from the Yale Human Investigation Committee (the committee 
that reviews, approves and monitors human subject research) may inspect study records 
during internal auditing procedures.  However, these individuals are required to keep all 
information confidential. 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
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You are free to choose not to participate and, if you do become a subject you are 
free to withdraw from this study at any time during its course. If you choose not to 
participate or if you withdraw, it will not harm your relationship with your own doctors 
or with Yale-New Haven hospital.  You do not give up any of your legal rights by signing 
this form. 
QUESTIONS 
We have used some technical terms in this form. Please feel free to ask about 
anything you don't understand and to consider this research and the consent form 
carefully as long as you feel is necessary before you make a decision.  
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AUTHORIZATION 
I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of involvement and possible 
hazards and inconveniences have been explained to my satisfaction.  My signature also 
indicates that I have received a copy of this consent form. 
 
Name of Subject:_____________________________ 
      






Signature of Principal Investigator  Date 
 
                                      or 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, Kali O’Dell.  If you have any questions 
concerning your rights as a research subject, you may contact the Human Investigation 
Committee at (203) 785-4688. 
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX 
HAS BEEN COMPLETED IN THE HIC OFFICE 
 
THIS FORM IS VALID  
FROM:_____________ UNTIL: _______________ 
HIC PROTOCOL #: _________________________ 
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INITIALED: ___________________________ 
APPENDIX III: RESEARCH PARTICIPANT CONSENT FORM: ENGLISH SHORT FORM 
 
SHORT FORM WRITTEN CONSENT 
FOR SUBJECTS WHO ARE UNABLE TO READ ENGLISH 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Probiotic therapy for the prevention of recurrent spontaneous preterm birth 
Principal Investigator: Kali O’Dell PA-S2 
 
CONSENT TO PARTICIPATE IN RESEARCH 
You are being asked to participate in a research study. 
Before you agree, the investigator must tell you about (i) the purposes, 
procedures, and duration of the research; (ii) any procedures which are experimental; 
(iii) any reasonably foreseeable risks, discomforts, and benefits of the research; (iv) any 
potentially beneficial alternative procedures or treatments; and (v) how confidentiality 
will be maintained. 
Where applicable, the investigator must also tell you about (i) any available 
compensation or medical treatment if injury occurs; (ii) the possibility of unforeseeable 
risks; (iii) circumstances when the investigator may halt your participation; (iv) any 
added costs to you; (v) what happens if you decide to stop participating; (vi) when you 
will be told about new findings which may affect your willingness to participate; and (vii) 
how many people will be in the study. 
If you agree to participate, you must be given a signed copy of this document 
and a written summary of the research. 
You may contact Kali O’Dell at the study number any time you have questions 
about the research or what to do if you are injured. You may contact the Yale Human 
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Research Protection Program (HRPP) at 203-785-4688 if you have questions about your 
rights as a research subject. 
Your participation in this research is voluntary, and you will not be penalized or 
lose benefits if you refuse to participate or decide to stop. 
Signing this document means that the research study, including the above 
information, has been described to you orally, and that you voluntarily agree to 
participate. 
_________________________________   _______________ 
Signature of Participant/LAR     Date 
 
 
__________________________________   ________________ 
Signature of Witness      Date 




By signing this form you are indicating that: 
• The information in the Summary Document (this is the short form) as well as 
any additional information conveyed by the research person obtaining 
consent was presented to the subject in a language preferred by and 
understandable to the subject 
• The subject’s questions were interpreted and the responses of the person 
obtaining consent were presented in a language preferred by and 
understandable to the subject. 
• At the conclusion of the consent conference the subject was asked in a 
language preferred by and understandable to the subject if s/he understood 
the information, and responded affirmatively. 
 
_________________________________  ______________ 











APPENDIX IV: RESEARCH PARTICIPANT CONSENT FORM: SPANISH SHORT FORM 
 
FORMULARIO ABREVIADO DE CONSENTIMIENTO ESCRITO 
PARA INDIVIDUOS QUE NO HABLAN NI LEEN EL INGLÉS 
ESCUELA DE MEDICINA DE LA UNIVERSIDAD DE YALE – HOSPITAL YALE-NEW HAVEN 
 
Nombre del estudio: Terapia probióticos para la prevención del nacimiento prematuro 
espontáneo 
Investigador principal: Kali O’Dell PA-S2 
 
CONSENTIMIENTO PARA PARTICIPAR EN LA INVESTIGACIÓN 
Se le está solicitando su participación en un estudio de investigación.  
Antes de aceptar, el investigador debe informarle sobre: (i) los propósitos, los 
procedimientos y la duración del estudio; (ii) todo procedimiento que sea experimental; 
(iii) todo posible riesgo, incomodidad o beneficio que se pueda prever como resultado del 
estudio; (iv) cualquier procedimiento o tratamiento alternativo que tenga potencial de 
beneficiarle; y (v) cómo se mantendrá la confidencialidad. 
Cuando sea aplicable, el investigador debe también informarle sobre: (i) cualquier 
compensación o atención médica disponible en caso de lesión; (ii) la posibilidad de riesgos 
impredecibles; (iii) situaciones en las que el investigador pueda cesar su participación; (iv) 
cualquier costo adicional para usted; (v) lo que pasa si usted decide interrumpir su 
participación; (vi) cuándo se le informará sobre nuevos hallazgos que puedan afectar su 
deseo en participar; (vii) cuántas personas participarán en el estudio; y su derecho de 
revocar (anular) su autorización para el uso o la divulgación de sus datos de salud 
confidenciales por parte de los investigadores. 
Si usted acepta participar, debe recibir una copia firmada de este documento y un 
resumen del estudio por escrito. 
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Puede comunicarse con Kali O'Dell al número de estudio a cualquier momento 
que tenga preguntas sobre el estudio o sobre lo que debe hacer si se encuentra herido. 
Puede comunicarse con el programa Yale Human Research Protection Program (HRPP) al 
203-785-4688 si tiene preguntas sobre sus derechos como sujeto de una investigación. 
Su participación en esta investigación es voluntaria, y usted no será penalizado ni 
perderá beneficios al negar su participación o al optar por interrumpirla. 
Al firmar este documento, usted consta que el estudio de investigación, 
incluyendo la información previa, le han sido explicadas oralmente, y que usted se presta 
voluntariamente a participar. 
_________________________________   _______________ 
Firma del participante/LAR     Fecha 
 
 
__________________________________   ________________ 
Firma del testigo      Fecha 




Al firmar este formulario, usted afirma que: 
• La información en el Documento Sumario (el formulario abreviado) y toda 
información adicional comunicada por el investigador obteniendo el 
consentimiento del sujeto le fue presentada al mismo en su idioma preferido 
y de manera comprensible.  
• Las preguntas del sujeto fueron interpretadas y las respuestas de la persona 
obteniendo el consentimiento le fueron transmitidas al sujeto en su idioma 
preferido y de manera comprensible.  
• Al cierre de la conferencia de consentimiento, se le preguntó al sujeto en su 
idioma preferido y de manera comprensible, si había comprendido la 
información, el cual este contestó en lo afirmativo. 
 
_________________________________  ______________ 
Firma del testigo/intérprete    Fecha 
 
NOTA: En caso de que un individuo con dominio de ambos idiomas firme de testigo (p. 
ej., un familiar), el intérprete no deberá firmar este formulario. Si el estudio requiere a 
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un testigo y el intérprete sirve de tal testigo, este deberá también firmar el sumario de 
consentimiento, (este es típicamente el formulario de consentimiento extenso 
aprobado por el IRB). 
APPENDIX V: BASELINE CHARCTERISTICS CASE REPORT FORM  
 PROBIOTIC THERAPY & PREVENTION OF PRETERM BIRTH, ENROLLMENT CRF                           page 1/3 
 
Subject Initials          Subject ID                 Date
   
BASELINE VARIABLES 
 
1. Subject Medical Record Number  
5. Birthdate    6. Weight (kg) 7. Height (cm) 
  
 
8. Weight before pregnancy (kg)  Estimate     EMR, date   
 
9. Gestational Age            weeks days    
10. Ethnicity (check one)  11. Race (check all that apply) 
 Hispanic   American Indian or Native American     
  Non-Hispanic   Asian           
  Unknown/Not-Reported    Black or African American 
    Native Hawaiian or Other Pacific Islander  
    White or Caucasian  
    Unknown or Not Reported 
Contact Information: 
Address: Unit #: 
City: State: Zip: 
 
Phone Number: ______________ 
Home Work Cell Other           
Alternate 
Phone Number: ________________ 
Home Work Cell Other    
Email address: 
 
Preferred method of contact: 




Address: Unit #: 
City: State: Zip: 
 
Phone Number: _______________ 
Home Work Cell Other    
Alternate 
Phone Number: _______________ 
Home Work Cell Other    
Email address: 
 
Do we have permission to contact this person if we cannot reach you? No protected health information 
will be given to this person.    Yes          No 
2. First Name: 
3. Middle Name (or initial): 
4. Last Name: 
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Form Completed By:          Date:     
 
 PROBIOTIC THERAPY & PREVENTION OF PRETERM BIRTH, ENROLLMENT CRF                            page 2/3 
 
Subject Initials          Subject ID                 Date  
 
PREGNANCY HISTORY 
12. Gestational age at delivery of qualifying  
previous spontaneous preterm birth:                   weeks days  
  
13. Number of previous spontaneous preterm births:       patient report   verified in EMR 
  
14. Gravidity:                        
 
15. Parity:  
 
16. Term Births: 17. Preterm births: 18. 
Abortions:  19. Living children:      
MEDICAL HISOTRY 
20. Pre-existing Medical Conditions: (check all that apply) 
  
 Systolic Heart Failure (EF <40%)     Renal Failure (CrCl <30) 
 Hypertension requiring medication    Diabetes Mellitus Type 2 
 Antiphospholipid Syndrome 
 
LIFESTYLE & SOCIOECONOMIC VARIABLES 
21. FINANCIAL: 
 
a. Combined annual household income:    Unknown 
 
 b. Receiving WIC:    Yes   No   Unknown 
 
22. EDUCATION: (check one and list grade/years if indicated) 
 
 Primary school only, highest grade completed:  
 
 Some high school, highest grade completed:  
 
  High school diploma or GED  
 
  Some College, number of years completed 
  
  Bachelor’s Degree  
 
  Some graduate school or graduate degree,  
       number of years beyond undergraduate   
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 No formal schooling 
  
Form Completed By:          Date:     
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Subject Initials          Subject ID                 Date 
   
LIFESTYLE & SOCIOECONOMIC VARIABLES – CONT’D 
23. MARITAL STATUS: (check the box that explains most current marital status) 
 
 Married     Currently unmarried, living with significant other 
 Divorced or Separated   Widowed 
 Never married, not living with significant other 
24. PHYSICAL ACTIVITY: (check one) 
  
 Never exercise 
 Light exercise, >1 time per week 
 Moderate exercise, 1-2 times per week   
 Frequent exercise, >3 times a week  
25. SUBSTANCE USE: 
  
a. Cigarette use before pregnancy:   Yes   No 
  
 
                                                                        If yes   packs per day for  years   
 
   Quit Date:  N/A 
 
b. Cigarette use during pregnancy:   Yes   No  
 
c. Alcohol use during pregnancy:   Yes   No 
  
d. Recreational drug use during pregnancy:  Yes   No 
 

















Form Completed By:          Date:     
APPENDIX VI: FOLLOW-UP CASE REPORT FORM  
 PROBIOTIC THERAPY & PREVENTION OF PRETERM BIRTH, FOLLOW-UP CRF                             page 1/2 
 
Subject Initials          Subject ID                 Date 
   
                                                Weeks Since Enrollment: Follow-Up Number:    
COMPLIANCE / ADHERENCE 
Beginning the first day after the last follow-up visit fill out the calendar with the dates from last follow-up 
to this follow-up. Mark with an X the days the patient was non-compliant/adherent with treatment. Make 
a copy of the patient’s recording sheet, file with this follow-up form:   








































__/__/__ __/__/__ __/__/__ __/__/__ __/__/__ __/__/__ 
 
1. Number of days compliant with tablet since last follow-up:  
 
 82 
2. Average number of days compliant/adherent per week: 
 
Form Completed By:          Date:     
 PROBIOTIC THERAPY & PREVENTION OF PRETERM BIRTH, FOLLOW-UP CRF                             page 2/2 
 
Subject Initials          Subject ID                 Date 
   
                                                Weeks Since Enrollment: Follow-Up Number:    
 
SIDE EFFECTS & ADVERSE EVENT MONITORING 
3. Please list any new physical symptoms or complaints the patient reports in the interval between this 








4. Indicate if the patient sought medical care for a new problem at their primary care center, the 
emergency department, or was admitted to the hospital for any reason in the interval between this visit 
and the last study visit:   
a. Primary care   Yes   No 
b. Emergency Dept.  Yes   No    If yes, what hospital ___________________ 
c. Admitted to Hospital  Yes   No If yes, what hospital ___________________ 
 
d.  Patient report only  Verified in EMR or with documentation from provider 
 
5. If yes to any of the above, list was the reason(s) for the hospital encounter and the resulting or 






a.  Patient report only  Verified in EMR or with documentation from provider 
 
6. If yes to any of the above, were medications prescribed:    Yes    No     Unknown 
 







b.  Patient report only  Verified in EMR or with documentation from provider 
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APPENDIX VII: PREGNANCY OUTCOMES CASE REPORT FORM  
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Subject Initials          Subject ID                 Date
   
PREGNANCY OUTCOMES 
 
1. Gestational age at delivery: weeks days      
 
2. If birth occurred before 37 completed weeks, please indicate the nature of the preterm delivery:  
   
   Spontaneous 
 
 Indicated 





3. Participant received 17 alpha-hydroxyprogesterone caproate during gestation:  Yes 
  No 
 




5. Fetal Death:     Yes   No   Unknown 
    
   a. If yes:   Antepartum  Intrapartum  Unknown 
 
   b. If yes: Gestational age: weeks days 
 
6. Birth weight (g):           Unknown               
  
7. Apgar score:        a. 1-minute b. 5 minute  
8. NICU admission:   Yes   No   Unknown 
    
a. If yes, length of stay: days (maximum 28)  
 Indicate if the following were provided between birth and 28 days of life: 
  
9.  Supplemental oxygen:   Yes   No   Unknown 
 84 
 
10. Mechanical ventilation:   Yes   No   Unknown 
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Subject Initials          Subject ID                 Date
   
NEONATAL OUTCOMES – CONT’D 
Indicate if the following were diagnosed between birth and 28 days of life: 
 
11. Transient tachypnea:    Yes   No   Unknown 
 
12. Respiratory distress syndrome:   Yes   No   Unknown 
 
13. Bronchopulmonary dysplasia:  Yes   No   Unknown 
 
14. Intraventricular hemorrhage:  Yes   No   Unknown 
 
   a. If yes:  Grade 1      Grade 2     Grade 3     Grade 4    Unknown 
 
15. Periventricular leukomalacia:  Yes   No   Unknown 
 
16. Necrotizing Enterocolitis:  Yes   No   Unknown 
 
17. Sepsis    Yes   No   Unknown 
 
18. Neonatal Death   Yes   No   Unknown 
MATERNAL OUTCOMES 
Indicate if the following were diagnosed between time of study enrollment and delivery:  
 
19. Diagnosed vaginal infection during gestation:  Yes   No   Unknown 
  
 a. Bacterial vaginosis:    Yes   No   Unknown 
 
 b. Aerobic vaginitis:    Yes   No   Unknown 
   
 c. Vulvovaginal candidiasis:   Yes   No   Unknown 
 
 d. Other:     Yes   No   Unknown 
 
20. Antibiotic use during gestation:    Yes   No   Unknown 
 
 a. If yes, was antibiotic for vaginal infection:  Yes   No   Unknown 
 
21. Pregnancy complications: 
  
 85 
 a. Clinical chorioamnionitis   Yes   No   Unknown 
 
b. Gestational diabetes:     Yes   No   Unknown 
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Subject Initials          Subject ID                 Date
   
MATERNAL OUTCOMES – CONT’D 
21. Pregnancy complications continued: 
 
 c. Preeclampsia or eclampsia:   Yes   No   Unknown 
 
 d. Placental abruption:    Yes   No   Unknown 
 
 e. Recurrent antepartum hemorrhage:  Yes   No   Unknown 
 
22. Preterm premature rupture of the membranes:  Yes   No   Unknown 
 
23. Admission for preterm labor:    Yes   No   Unknown 
 
24. Tocolytic therapy for preterm labor:   Yes   No   Unknown 
 
25. Antepartum corticosteroid administration 
      for fetal lung maturity:     Yes   No   Unknown 
 
Indicate if the following were diagnosed upon delivery or within 28 days postpartum: 
 
26. Postnatal endometritis:  Yes   No   Unknown 
 
27. Postnatal sepsis:   Yes   No   Unknown 
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APPENDIX VIII: VAGINAL SPECIMEN COLLECTION FORM  
VAGINAL SPECIMEN COLLECTION CRF                                                         page 1/1 
 
Subject Initials          Subject ID                 Date
   
1. Indicate the follow-up visit this specimen corresponds to:  
 
  T0: Enrollment 
 
 T2: 8 weeks after enrollment 
 
 T3: 16 weeks after enrollment 
 
 T4: 24 weeks after enrollment 
 
 
2. Current gestational age: weeks  days    
 
 
3. Specimen was collected from:    Posterior Vaginal Fornix   ID Number _______________ 
 
     Lateral Vaginal Wall        ID Number _______________ 
 
     No specimen(s) collected 
 
 
4. Specimen was collected by: __________________________ (print)  
 
                                             __________________________ (sign)                   Date:  
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APPENDIX IX: PARTICIPANT TABLET RECORDING LOG  
PROBIOTIC THERAPY & PREVENTION OF PRETERM BIRTH: PARTICIPANT RECORDING DOCUMENT                page 1/10 
 
 Initials/Iniciales _________  Name/Nombre:_______________________  
 
Instructions: Fill in the date that you begin taking the tablets and every date after. Mark an X on the days 
you take the tablet, write the time you take the tablet next to the X, and circle if you took the tablet in the 
morning (am) or afternoon/evening (pm). See the example below. 
 
Instrucciones: Rellene la fecha en que tomaste la primera tablet. Asegúrese de que la fecha es en el día de 
la semana correcto. Rellene todas las fechas siguientes. Escribir X en los días que usted toma la tableta, 
anote la hora toma la tableta, y el círculo si usted tomo la tableta en la mañana (am) o por la tarde / 
noche (pm) 
 
Example of one week of recording. The participant forgot the tablet on Friday, so no X was marked. 
Ejemplo de uno semana de grabación: El participante se olvidó la tableta en viernes, es por eso que no 











































06:32      am/pm 
 
Start Recording Here: 































































































































_ _:_ _ am/pm 
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_ _:_ _ am/pm 




_ _:_ _ am/pm 
__  
 
_ _:_ _ am/pm 
__  
 
_ _:_ _ am/pm 
__  
 
_ _:_ _ am/pm 
__  
 
_ _:_ _ am/pm 
__  
 
_ _:_ _ am/pm 
__  
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